Issazadeh S, Abdallah K, Chitnis T, Chandraker A, Wells AD, Turka LA, Sayegh MH, Khoury SJ
Role of passive T-cell death in chronic experimental autoimmune encephalomyelitis. J Clin Invest. 2000 Apr; 105(8):1109-16.
Role of passive T-cell death in chronic experimental autoimmune encephalomyelitis.
T cell costimulatory pathways: blockade for autoimmunity. Expert Opin Biol Ther. 2003 Apr; 3(2):227-36.
T cell costimulatory pathways: blockade for autoimmunity.
Blocking costimulatory signals to induce transplantation tolerance and prevent autoimmune disease. Int Rev Immunol. 1999; 18(3):185-99.
Blocking costimulatory signals to induce transplantation tolerance and prevent autoimmune disease.
Kishimoto K, Dong VM, Issazadeh S, Fedoseyeva EV, Waaga AM, Yamada A, Sho M, Benichou G, Auchincloss H, Grusby MJ, Khoury SJ, Sayegh MH
The role of CD154-CD40 versus CD28-B7 costimulatory pathways in regulating allogeneic Th1 and Th2 responses in vivo. J Clin Invest. 2000 Jul; 106(1):63-72.
The role of CD154-CD40 versus CD28-B7 costimulatory pathways in regulating allogeneic Th1 and Th2 responses in vivo.
Chitnis T, Imitola J, Wang Y, Elyaman W, Chawla P, Sharuk M, Raddassi K, Bronson RT, Khoury SJ
Elevated neuronal expression of CD200 protects Wlds mice from inflammation-mediated neurodegeneration. Am J Pathol. 2007 May; 170(5):1695-712.
Elevated neuronal expression of CD200 protects Wlds mice from inflammation-mediated neurodegeneration.
Khoury SJ, Healy BC, Kivisäkk P, Viglietta V, Egorova S, Guttmann CR, Wedgwood JF, Hafler DA, Weiner HL, Buckle G, Cook S, Reddy S
A randomized controlled double-masked trial of albuterol add-on therapy in patients with multiple sclerosis. Arch Neurol. 2010 Sep; 67(9):1055-61.
A randomized controlled double-masked trial of albuterol add-on therapy in patients with multiple sclerosis.
Imitola J, Park KI, Teng YD, Nisim S, Lachyankar M, Ourednik J, Mueller FJ, Yiou R, Atala A, Sidman RL, Tuszynski M, Khoury SJ, Snyder EY
Philosophical transactions of the Royal Society of London. Series B, Biological sciences
Stem cells: cross-talk and developmental programs. Philos Trans R Soc Lond B Biol Sci. 2004 May 29; 359(1445):823-37.
Stem cells: cross-talk and developmental programs.
Cytokines in multiple sclerosis: from bench to bedside. Pharmacol Ther. 2005 May; 106(2):163-77.
Cytokines in multiple sclerosis: from bench to bedside.
Villoslada P, Moreno B, Melero I, Pablos JL, Martino G, Uccelli A, Montalban X, Avila J, Rivest S, Acarin L, Appel S, Khoury SJ, McGeer P, Ferrer I, Delgado M, Obeso J, Schwartz M
Immunotherapy for neurological diseases. Clin Immunol. 2008 Sep; 128(3):294-305.
Immunotherapy for neurological diseases.
Longbrake EE, Kantor D, Pawate S, Bradshaw MJ, von Geldern G, Chahin S, Cross AH, Parks BJ, Rice M, Khoury SJ, Yamout B, Zeineddine M, Russell-Giller S, Caminero-Rodriguez A, Edwards K, Lathi E, VanderKodde D, Meador W, Berkovich R, Ge L, Bacon TE, Kister I
Effectiveness of alternative dose fingolimod for multiple sclerosis. Neurol Clin Pract. 2018 Apr; 8(2):102-107.
Effectiveness of alternative dose fingolimod for multiple sclerosis.
Neuroimmunology. Neurology in Clinical Practice. 1999; 805-822.
Khoury SJ, Sayegh MH, Hancock WW, Gallon L, Carpenter CB, Weiner HL
Acquired tolerance to experimental autoimmune encephalomyelitis by intrathymic injection of myelin basic protein or its major encephalitogenic peptide. J Exp Med. 1993 Aug 01; 178(2):559-66.
Acquired tolerance to experimental autoimmune encephalomyelitis by intrathymic injection of myelin basic protein or its major encephalitogenic peptide.
Elyaman W, Bradshaw EM, Wang Y, Oukka M, Kivisäkk P, Chiba S, Yagita H, Khoury SJ
Journal of immunology (Baltimore, Md. : 1950)
JAGGED1 and delta1 differentially regulate the outcome of experimental autoimmune encephalomyelitis. J Immunol. 2007 Nov 01; 179(9):5990-8.
JAGGED1 and delta1 differentially regulate the outcome of experimental autoimmune encephalomyelitis.
Wang Y, Imitola J, Rasmussen S, O'Connor KC, Khoury SJ
Paradoxical dysregulation of the neural stem cell pathway sonic hedgehog-Gli1 in autoimmune encephalomyelitis and multiple sclerosis. Ann Neurol. 2008 Oct; 64(4):417-27.
Paradoxical dysregulation of the neural stem cell pathway sonic hedgehog-Gli1 in autoimmune encephalomyelitis and multiple sclerosis.
Cerebral pseudoatrophy or real atrophy after therapy in multiple sclerosis. Ann Neurol. 2010 Dec; 68(6):778-9.
Cerebral pseudoatrophy or real atrophy after therapy in multiple sclerosis.
The Journal of allergy and clinical immunology
20. Immunologic neuromuscular disorders. J Allergy Clin Immunol. 2003 Feb; 111(2 Suppl):S659-68.
20. Immunologic neuromuscular disorders.
Role of costimulatory pathways in the pathogenesis of multiple sclerosis and experimental autoimmune encephalomyelitis. J Allergy Clin Immunol. 2003 Nov; 112(5):837-49; quiz 850.
Role of costimulatory pathways in the pathogenesis of multiple sclerosis and experimental autoimmune encephalomyelitis.
Kutok JL, Yang X, Folkerth RD, Imitola J, Raddassi K, Yano Y, Salahuddin S, Lawitts J, Imboden H, Chinami M, Shirakawa T, Turner H, Khoury S, Sayegh MH, Scadden D, Adra C
The cell cycle associated protein, HTm4, is expressed in differentiating cells of the hematopoietic and central nervous system in mice. J Mol Histol. 2005 Feb; 36(1-2):77-87.
The cell cycle associated protein, HTm4, is expressed in differentiating cells of the hematopoietic and central nervous system in mice.
Karni, A., K. Makhlouf, S.J. Khoury, H.L. Weiner
Brain Disease: Therapeutic Strategies and Repair
Immunomodulation And Therapy In Multiple Sclerosis. Brain Disease: Therapeutic Strategies and Repair. 2001; 73-82.
Immunomodulation And Therapy In Multiple Sclerosis
Starossom SC, Mascanfroni ID, Imitola J, Cao L, Raddassi K, Hernandez SF, Bassil R, Croci DO, Cerliani JP, Delacour D, Wang Y, Elyaman W, Khoury SJ, Rabinovich GA
Galectin-1 deactivates classically activated microglia and protects from inflammation-induced neurodegeneration. Immunity. 2012 Aug 24; 37(2):249-63.
Galectin-1 deactivates classically activated microglia and protects from inflammation-induced neurodegeneration.
T cell abnormalities in Multiple Sclerosis. Handbook of Multiple Sclerosis. 1990; 129-149.
T cell abnormalities in Multiple Sclerosis
Rasmussen S, Imitola J, Ayuso-Sacido A, Wang Y, Starossom SC, Kivisäkk P, Zhu B, Meyer M, Bronson RT, Garcia-Verdugo JM, Khoury SJ
Reversible neural stem cell niche dysfunction in a model of multiple sclerosis. Ann Neurol. 2011 May; 69(5):878-91.
Reversible neural stem cell niche dysfunction in a model of multiple sclerosis.
Ottoboni L, Keenan BT, Tamayo P, Kuchroo M, Mesirov JP, Buckle GJ, Khoury SJ, Hafler DA, Weiner HL, De Jager PL
An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity. Sci Transl Med. 2012 Sep 26; 4(153):153ra131.
An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity.
Weiner HL, Zhang ZJ, Khoury SJ, Miller A, al-Sabbagh A, Brod SA, Lider O, Higgins P, Sobel R, Nussenblatt RB
Annals of the New York Academy of Sciences
Antigen-driven peripheral immune tolerance. Suppression of organ-specific autoimmune diseases by oral administration of autoantigens. Ann N Y Acad Sci. 1991 Dec 30; 636:227-32.
Antigen-driven peripheral immune tolerance. Suppression of organ-specific autoimmune diseases by oral administration of autoantigens.
Karni A, Balashov K, Hancock WW, Bharanidharan P, Abraham M, Khoury SJ, Weiner HL
Cyclophosphamide modulates CD4+ T cells into a T helper type 2 phenotype and reverses increased IFN-gamma production of CD8+ T cells in secondary progressive multiple sclerosis. J Neuroimmunol. 2004 Jan; 146(1-2):189-98.
Cyclophosphamide modulates CD4+ T cells into a T helper type 2 phenotype and reverses increased IFN-gamma production of CD8+ T cells in secondary progressive multiple sclerosis.
Yamout BI, Sahraian MA, Ayoubi NE, Tamim H, Nicolas J, Khoury SJ, Zeineddine MM
Multiple sclerosis and related disorders
Efficacy and safety of natalizumab extended interval dosing. Mult Scler Relat Disord. 2018 Aug; 24:113-116.
Efficacy and safety of natalizumab extended interval dosing.
Xiao S, Najafian N, Reddy J, Albin M, Zhu C, Jensen E, Imitola J, Korn T, Anderson AC, Zhang Z, Gutierrez C, Moll T, Sobel RA, Umetsu DT, Yagita H, Akiba H, Strom T, Sayegh MH, DeKruyff RH, Khoury SJ, Kuchroo VK
Differential engagement of Tim-1 during activation can positively or negatively costimulate T cell expansion and effector function. J Exp Med. 2007 Jul 09; 204(7):1691-702.
Differential engagement of Tim-1 during activation can positively or negatively costimulate T cell expansion and effector function.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
Modulating co-stimulation. Neurotherapeutics. 2007 Oct; 4(4):666-75.
Ceccarelli A, Jackson JS, Tauhid S, Arora A, Gorky J, Dell'Oglio E, Bakshi A, Chitnis T, Khoury SJ, Weiner HL, Guttmann CR, Bakshi R, Neema M
AJNR. American journal of neuroradiology
The impact of lesion in-painting and registration methods on voxel-based morphometry in detecting regional cerebral gray matter atrophy in multiple sclerosis. AJNR Am J Neuroradiol. 2012 Sep; 33(8):1579-85.
The impact of lesion in-painting and registration methods on voxel-based morphometry in detecting regional cerebral gray matter atrophy in multiple sclerosis.
Gandhi R, Healy B, Gholipour T, Egorova S, Musallam A, Hussain MS, Nejad P, Patel B, Hei H, Khoury S, Quintana F, Kivisakk P, Chitnis T, Weiner HL
Circulating microRNAs as biomarkers for disease staging in multiple sclerosis. Ann Neurol. 2013 Jun; 73(6):729-40.
Circulating microRNAs as biomarkers for disease staging in multiple sclerosis.
Khoury SJ, Gallon L, Chen W, Betres K, Russell ME, Hancock WW, Carpenter CB, Sayegh MH, Weiner HL
Mechanisms of acquired thymic tolerance in experimental autoimmune encephalomyelitis: thymic dendritic-enriched cells induce specific peripheral T cell unresponsiveness in vivo. J Exp Med. 1995 Aug 01; 182(2):357-66.
Mechanisms of acquired thymic tolerance in experimental autoimmune encephalomyelitis: thymic dendritic-enriched cells induce specific peripheral T cell unresponsiveness in vivo.
Healy BC, Ali EN, Guttmann CR, Chitnis T, Glanz BI, Buckle G, Houtchens M, Stazzone L, Moodie J, Berger AM, Duan Y, Bakshi R, Khoury S, Weiner H, Ascherio A
Smoking and disease progression in multiple sclerosis. Arch Neurol. 2009 Jul; 66(7):858-64.
Smoking and disease progression in multiple sclerosis.
Weiner HL, Mackin GA, Matsui M, Orav EJ, Khoury SJ, Dawson DM, Hafler DA
Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science. 1993 Feb 26; 259(5099):1321-4.
Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis.
Kappa light chains in spinal fluid for diagnosing multiple sclerosis. JAMA. 1994 Jul 20; 272(3):242-3.
Kappa light chains in spinal fluid for diagnosing multiple sclerosis.
Hannoun S, Baalbaki M, Haddad R, Saaybi S, El Ayoubi NK, Yamout BI, Khoury SJ, Hourani R
Gadolinium effect on thalamus and whole brain tissue segmentation. Neuroradiology. 2018 Nov; 60(11):1167-1173.
Gadolinium effect on thalamus and whole brain tissue segmentation.
Regev K, Healy BC, Paul A, Diaz-Cruz C, Mazzola MA, Raheja R, Glanz BI, Kivisäkk P, Chitnis T, Jagodic M, Piehl F, Olsson T, Khademi M, Hauser S, Oksenberg J, Khoury SJ, Weiner HL, Gandhi R
Neurology(R) neuroimmunology & neuroinflammation
Identification of MS-specific serum miRNAs in an international multicenter study. Neurol Neuroimmunol Neuroinflamm. 2018 Sep; 5(5):e491.
Identification of MS-specific serum miRNAs in an international multicenter study.
Beriou G, Bradshaw EM, Lozano E, Costantino CM, Hastings WD, Orban T, Elyaman W, Khoury SJ, Kuchroo VK, Baecher-Allan C, Hafler DA
TGF-beta induces IL-9 production from human Th17 cells. J Immunol. 2010 Jul 01; 185(1):46-54.
TGF-beta induces IL-9 production from human Th17 cells.
Xia Z, Chibnik LB, Glanz BI, Liguori M, Shulman JM, Tran D, Khoury SJ, Chitnis T, Holyoak T, Weiner HL, Guttmann CR, De Jager PL
A putative Alzheimer's disease risk allele in PCK1 influences brain atrophy in multiple sclerosis. PLoS One. 2010 Nov 30; 5(11):e14169.
A putative Alzheimer's disease risk allele in PCK1 influences brain atrophy in multiple sclerosis.
Methods in molecular biology (Clifton, N.J.)
Neural stem cells and the future treatment of neurological diseases: raising the standard. Methods Mol Biol. 2008; 438:9-16.
Neural stem cells and the future treatment of neurological diseases: raising the standard.
De Jager PL, Rossin E, Pyne S, Tamayo P, Ottoboni L, Viglietta V, Weiner M, Soler D, Izmailova E, Faron-Yowe L, O'Brien C, Freeman S, Granados S, Parker A, Roubenoff R, Mesirov JP, Khoury SJ, Hafler DA, Weiner HL
Cytometric profiling in multiple sclerosis uncovers patient population structure and a reduction of CD8low cells. Brain. 2008 Jul; 131(Pt 7):1701-11.
Cytometric profiling in multiple sclerosis uncovers patient population structure and a reduction of CD8low cells.
Dardalhon V, Awasthi A, Kwon H, Galileos G, Gao W, Sobel RA, Mitsdoerffer M, Strom TB, Elyaman W, Ho IC, Khoury S, Oukka M, Kuchroo VK
IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells. Nat Immunol. 2008 Dec; 9(12):1347-55.
IL-4 inhibits TGF-beta-induced Foxp3+ T cells and, together with TGF-beta, generates IL-9+ IL-10+ Foxp3(-) effector T cells.
Healy BC, Liguori M, Tran D, Chitnis T, Glanz B, Wolfish C, Gauthier S, Buckle G, Houtchens M, Stazzone L, Khoury S, Hartzmann R, Fernandez-Vina M, Hafler DA, Weiner HL, Guttmann CR, De Jager PL
HLA B*44: protective effects in MS susceptibility and MRI outcome measures. Neurology. 2010 Aug 17; 75(7):634-40.
HLA B*44: protective effects in MS susceptibility and MRI outcome measures.
Th17 and Treg balance in systemic sclerosis. Clin Immunol. 2011 Jun; 139(3):231-2.
Th17 and Treg balance in systemic sclerosis.
Cousens LP, Najafian N, Mingozzi F, Elyaman W, Mazer B, Moise L, Messitt TJ, Su Y, Sayegh M, High K, Khoury SJ, Scott DW, De Groot AS
In vitro and in vivo studies of IgG-derived Treg epitopes (Tregitopes): a promising new tool for tolerance induction and treatment of autoimmunity. J Clin Immunol. 2013 Jan; 33 Suppl 1:S43-9.
In vitro and in vivo studies of IgG-derived Treg epitopes (Tregitopes): a promising new tool for tolerance induction and treatment of autoimmunity.
Weiner HL, Hohol MJ, Khoury SJ, Dawson DM, Hafler DA
Therapy for multiple sclerosis. Neurol Clin. 1995 Feb; 13(1):173-96.
Said M, El Ayoubi NK, Hannoun S, Haddad R, Saba L, Jalkh Y, Yamout BI, Khoury SJ
The Bayesian risk estimate at onset (BREMSO) correlates with cognitive and physical disability in patients with early multiple sclerosis. Mult Scler Relat Disord. 2018 Nov; 26:96-102.
The Bayesian risk estimate at onset (BREMSO) correlates with cognitive and physical disability in patients with early multiple sclerosis.
Camelo S, Iglesias AH, Hwang D, Due B, Ryu H, Smith K, Gray SG, Imitola J, Duran G, Assaf B, Langley B, Khoury SJ, Stephanopoulos G, De Girolami U, Ratan RR, Ferrante RJ, Dangond F
Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. J Neuroimmunol. 2005 Jul; 164(1-2):10-21.
Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis.
Liptak Z, Berger AM, Sampat MP, Charil A, Felsovalyi O, Healy BC, Hildenbrand P, Khoury SJ, Weiner HL, Bakshi R, Guttmann CR
Medulla oblongata volume: a biomarker of spinal cord damage and disability in multiple sclerosis. AJNR Am J Neuroradiol. 2008 Sep; 29(8):1465-70.
Medulla oblongata volume: a biomarker of spinal cord damage and disability in multiple sclerosis.
Parr MJ, Wen PY, Schaub M, Khoury SJ, Sayegh MH, Fine HA
Immune parameters affecting adenoviral vector gene therapy in the brain. J Neurovirol. 1998 Apr; 4(2):194-203.
Immune parameters affecting adenoviral vector gene therapy in the brain.
Khoury SJ, Akalin E, Chandraker A, Turka LA, Linsley PS, Sayegh MH, Hancock WW
CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system. J Immunol. 1995 Nov 15; 155(10):4521-4.
CD28-B7 costimulatory blockade by CTLA4Ig prevents actively induced experimental autoimmune encephalomyelitis and inhibits Th1 but spares Th2 cytokines in the central nervous system.
Khoury SJ, Guttmann CR, Orav EJ, Hohol MJ, Ahn SS, Hsu L, Kikinis R, Mackin GA, Jolesz FA, Weiner HL
Longitudinal MRI in multiple sclerosis: correlation between disability and lesion burden. Neurology. 1994 Nov; 44(11):2120-4.
Longitudinal MRI in multiple sclerosis: correlation between disability and lesion burden.
Weiner HL, Miller A, Khoury SJ, Zhang ZJ, al-Sabbagh A, Brod SA, Lider O, Higgins P, Sobel R, Matsui M
Advances in experimental medicine and biology
Treatment of autoimmune diseases by oral tolerance to autoantigens. Adv Exp Med Biol. 1995; 371B:1217-23.
Treatment of autoimmune diseases by oral tolerance to autoantigens.
Chitnis T, Najafian N, Benou C, Salama AD, Grusby MJ, Sayegh MH, Khoury SJ
Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis. J Clin Invest. 2001 Sep; 108(5):739-47.
Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis.
Fukaura, H., S.C. Kent, M.J. Pietrusewicz, S.J. Khoury, H.L. Weiner, and D.A. Hafler
Antigen-specific TGF-beta1 secretion with bovine myelin oral tolerization in multiple sclerosis. 1996; 251-257.
Antigen-specific TGF-beta1 secretion with bovine myelin oral tolerization in multiple sclerosis
Olek, M.J., M.J. Hohol, S.J. Khoury, D.M. Dawson, D.A. Hafler, H.L. Weiner.
Multiple sclerosis: therapeutic overviewStuart D. Cook. Handbook of Multiple Sclerosis. 1996; 377-396.
Multiple sclerosis: therapeutic overviewStuart D. Cook
Cytokine shifts and tolerance in experimental autoimmune encephalomyelitis. Immunol Res. 2003; 28(3):223-39.
Cytokine shifts and tolerance in experimental autoimmune encephalomyelitis.
Friedman A, al-Sabbagh A, Santos LM, Fishman-Lobell J, Polanski M, Das MP, Khoury SJ, Weiner HL
Oral tolerance: a biologically relevant pathway to generate peripheral tolerance against external and self antigens. Chem Immunol. 1994; 58:259-90.
Oral tolerance: a biologically relevant pathway to generate peripheral tolerance against external and self antigens.
Lavigne GJ, Khoury S, Abe S, Yamaguchi T, Raphael K
Bruxism physiology and pathology: an overview for clinicians. J Oral Rehabil. 2008 Jul; 35(7):476-94.
Bruxism physiology and pathology: an overview for clinicians.
Wang Y, Evans JT, Rodriguez F, Fields P, Mueller C, Chitnis T, Khoury SJ, Bynoe MS
A tale of two STAT6 knock out mice in the induction of experimental autoimmune encephalomyelitis. J Neuroimmunol. 2009 Jan 03; 206(1-2):76-85.
A tale of two STAT6 knock out mice in the induction of experimental autoimmune encephalomyelitis.
Hannoun S, Issa R, El Ayoubi NK, Haddad R, Baalbaki M, Yamout BI, Khoury SJ, Hourani R
Gadoterate Meglumine Administration in Multiple Sclerosis has no Effect on the Dentate Nucleus and the Globus Pallidus Signal Intensities. Acad Radiol. 2019 10; 26(10):e284-e291.
Gadoterate Meglumine Administration in Multiple Sclerosis has no Effect on the Dentate Nucleus and the Globus Pallidus Signal Intensities.
Makhlouf K, Comabella M, Imitola J, Weiner HL, Khoury SJ
Oral salbutamol decreases IL-12 in patients with secondary progressive multiple sclerosis. J Neuroimmunol. 2001 Jul 02; 117(1-2):156-65.
Oral salbutamol decreases IL-12 in patients with secondary progressive multiple sclerosis.
Karni A, Abraham M, Monsonego A, Cai G, Freeman GJ, Hafler D, Khoury SJ, Weiner HL
Innate immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response. J Immunol. 2006 Sep 15; 177(6):4196-202.
Innate immunity in multiple sclerosis: myeloid dendritic cells in secondary progressive multiple sclerosis are activated and drive a proinflammatory immune response.
Yamout BI, El-Ayoubi NK, Nicolas J, El Kouzi Y, Khoury SJ, Zeineddine MM
Safety and Efficacy of Rituximab in Multiple Sclerosis: A Retrospective Observational Study. J Immunol Res. 2018; 2018:9084759.
Safety and Efficacy of Rituximab in Multiple Sclerosis: A Retrospective Observational Study.
Starossom SC, Campo Garcia J, Woelfle T, Romero-Suarez S, Olah M, Watanabe F, Cao L, Yeste A, Tukker JJ, Quintana FJ, Imitola J, Witzel F, Schmitz D, Morkel M, Paul F, Infante-Duarte C, Khoury SJ
Chi3l3 induces oligodendrogenesis in an experimental model of autoimmune neuroinflammation. Nat Commun. 2019 01 15; 10(1):217.
Chi3l3 induces oligodendrogenesis in an experimental model of autoimmune neuroinflammation.
Kivisäkk P, Imitola J, Rasmussen S, Elyaman W, Zhu B, Ransohoff RM, Khoury SJ
Localizing central nervous system immune surveillance: meningeal antigen-presenting cells activate T cells during experimental autoimmune encephalomyelitis. Ann Neurol. 2009 Apr; 65(4):457-69.
Localizing central nervous system immune surveillance: meningeal antigen-presenting cells activate T cells during experimental autoimmune encephalomyelitis.
Glatigny S, Höllbacher B, Motley SJ, Tan C, Hundhausen C, Buckner JH, Smilek D, Khoury SJ, Ding L, Qin T, Pardo J, Nepom GT, Turka LA, Harris KM, Campbell DJ, Bettelli E
Abatacept Targets T Follicular Helper and Regulatory T Cells, Disrupting Molecular Pathways That Regulate Their Proliferation and Maintenance. J Immunol. 2019 03 01; 202(5):1373-1382.
Abatacept Targets T Follicular Helper and Regulatory T Cells, Disrupting Molecular Pathways That Regulate Their Proliferation and Maintenance.
Disorders of myelin in the central and peripheral nervous system
Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis: from bench to bedside. Disorders of myelin in the central and peripheral nervous system. 2002; 139-154.
Experimental Autoimmune Encephalomyelitis and Multiple Sclerosis: from bench to bedside
Fukaura H, Kent SC, Pietrusewicz MJ, Khoury SJ, Weiner HL, Hafler DA
Antigen-specific TGF-beta1 secretion with bovine myelin oral tolerization in multiple sclerosis. Ann N Y Acad Sci. 1996 Feb 13; 778:251-7.
Antigen-specific TGF-beta1 secretion with bovine myelin oral tolerization in multiple sclerosis.
Encephalomyelitis, Autoimmune, Experimental
Chehabeddine L, Al Saleh T, Baalbaki M, Saleh E, Khoury SJ, Hannoun S
Cumulative administrations of gadolinium-based contrast agents: risks of accumulation and toxicity of linear vs macrocyclic agents. Crit Rev Toxicol. 2019 03; 49(3):262-279.
Cumulative administrations of gadolinium-based contrast agents: risks of accumulation and toxicity of linear vs macrocyclic agents.
Jack, Sadie and David Breakstone Professor of Neurology, Emeritus
Albert H. Coons Professor of Neurology in the Field of Immunologic Diseases
Alroughani R, Akhtar S, Zeineddine M, El Kouzi Y, El Ayoubi NK, Ahmed SF, Behbehani R, Khoury SJ, Al-Hashel JY, Yamout BI
Risk of relapses during pregnancy among multiple sclerosis patients. Mult Scler Relat Disord. 2019 Sep; 34:9-13.
Risk of relapses during pregnancy among multiple sclerosis patients.
Jack, Sadie and David Breakstone Professor of Neurology
Samuel L. Wasserstrom Professor of Neurology
Maalouf FT, Alamiri B, Atweh S, Becker AE, Cheour M, Darwish H, Ghandour LA, Ghuloum S, Hamze M, Karam E, Khoury B, Khoury SJ, Mokdad A, Meho LI, Okasha T, Reed GM, Sbaity E, Zeinoun P, Akl EA
Mental health research in the Arab region: challenges and call for action. Lancet Psychiatry. 2019 11; 6(11):961-966.
Mental health research in the Arab region: challenges and call for action.
Yamout B, Sahraian M, Bohlega S, Al-Jumah M, Goueider R, Dahdaleh M, Inshasi J, Hashem S, Alsharoqi I, Khoury S, Alkhawajah M, Koussa S, Al Khaburi J, Almahdawi A, Alsaadi T, Slassi E, Daodi S, Zakaria M, Alroughani R
Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines. Mult Scler Relat Disord. 2020 Jan; 37:101459.
Consensus recommendations for the diagnosis and treatment of multiple sclerosis: 2019 revisions to the MENACTRIMS guidelines.
Tamim H, Zeineldine S, Tabbara F, Khoury S, Akiki Z, Khansa S, Taher A
Structure and evaluation of a residency research program in a university hospital. BMC Med Educ. 2019 Nov 06; 19(1):406.
Structure and evaluation of a residency research program in a university hospital.
Co-signaling Molecules in Neurological Diseases. Adv Exp Med Biol. 2019; 1189:233-265.
Co-signaling Molecules in Neurological Diseases.
"No evidence of disease activity": Is it an aspirational therapeutic goal in multiple sclerosis? Mult Scler Relat Disord. 2020 May; 40:101935.
"No evidence of disease activity": Is it an aspirational therapeutic goal in multiple sclerosis?
Darwish H, Farran N, Hannoun S, Tadros N, Yamout B, El Ayoubi NK, Khoury SJ
The Journal of steroid biochemistry and molecular biology
Serum vitamin D level is associated with speed of processing in multiple sclerosis patients. J Steroid Biochem Mol Biol. 2020 06; 200:105628.
Serum vitamin D level is associated with speed of processing in multiple sclerosis patients.
Amor S, Baker D, Khoury SJ, Schmierer K, Giovanonni G
SARS-CoV-2 and Multiple Sclerosis: Not All Immune Depleting DMTs are Equal or Bad. Ann Neurol. 2020 06; 87(6):794-797.
SARS-CoV-2 and Multiple Sclerosis: Not All Immune Depleting DMTs are Equal or Bad.
Zeinoun P, Farran N, Khoury SJ, Darwish H
Journal of clinical and experimental neuropsychology
Development, psychometric properties, and pilot norms of the first Arabic indigenous memory test: The Verbal Memory Arabic Test (VMAT). J Clin Exp Neuropsychol. 2020 07; 42(5):505-515.
Development, psychometric properties, and pilot norms of the first Arabic indigenous memory test: The Verbal Memory Arabic Test (VMAT).
Progressive Multiple Sclerosis. Ann Neurol. 2020 09; 88(3):436-437.
Darwish H, Zeinoun P, Farran N, Ghusn H, Yamout B, Khoury SJ
Journal of the International Neuropsychological Society : JINS
The Brief International Cognitive Assessment in Multiple Sclerosis (BICAMS): Validation in Arabic and Lebanese Normative Values. J Int Neuropsychol Soc. 2022 01; 28(1):94-103.
The Brief International Cognitive Assessment in Multiple Sclerosis (BICAMS): Validation in Arabic and Lebanese Normative Values.
Jaafar N, Khoueiry M, Khoury SJ, Makki A
Rare Case of Spinal Neurosarcoidosis with Concomitant Epidural Lipomatosis. Case Rep Neurol Med. 2021; 2021:5952724.
Rare Case of Spinal Neurosarcoidosis with Concomitant Epidural Lipomatosis.
Exosomes From Subjects With Multiple Sclerosis Express EBV-Derived Proteins and Activate Monocyte-Derived Macrophages. Neurol Neuroimmunol Neuroinflamm. 2021 07; 8(4).
Exosomes From Subjects With Multiple Sclerosis Express EBV-Derived Proteins and Activate Monocyte-Derived Macrophages.
El Ayoubi NK, Bou Reslan SW, Baalbaki MM, Darwish H, Khoury SJ
Effect of fingolimod vs interferon treatment on OCT measurements and cognitive function in RRMS. Mult Scler Relat Disord. 2021 Aug; 53:103041.
Effect of fingolimod vs interferon treatment on OCT measurements and cognitive function in RRMS.
Saba ES, Karout M, Nasrallah L, Kobeissy F, Darwish H, Khoury SJ
Long-term cognitive deficits after traumatic brain injury associated with microglia activation. Clin Immunol. 2021 09; 230:108815.
Long-term cognitive deficits after traumatic brain injury associated with microglia activation.
Dahham J, Rizk R, Hiligsmann M, Daccache C, Khoury SJ, Darwish H, Evers S, Kremer I
Expert review of pharmacoeconomics & outcomes research
The Economic and societal burden of multiple sclerosis on lebanese society: a cost-of-illness and quality of life study protocol. Expert Rev Pharmacoecon Outcomes Res. 2022 Jul; 22(5):869-876.
The Economic and societal burden of multiple sclerosis on lebanese society: a cost-of-illness and quality of life study protocol.
Chaaban L, Safwan N, Moussa H, El-Sammak S, Khoury SJ, Hannoun S
Central vein sign: A putative diagnostic marker for multiple sclerosis. Acta Neurol Scand. 2022 Mar; 145(3):279-287.
Central vein sign: A putative diagnostic marker for multiple sclerosis.
Multiple sclerosis journal - experimental, translational and clinical
Multiple sclerosis in the Middle East and North Africa region. Mult Scler J Exp Transl Clin. 2020 Jan-Mar; 6(1):2055217319895540.
Multiple sclerosis in the Middle East and North Africa region.
Abrams P, Chapple C, Khoury S, Roehrborn C, de la Rosette J
Evaluation and treatment of lower urinary tract symptoms in older men. J Urol. 2009 Apr; 181(4):1779-87.
Evaluation and treatment of lower urinary tract symptoms in older men.
Hitti E, Hadid D, Khoury SJ, Tamim H, Makki M, Karam CM
Domestic tethers: Gender differences in career paths and domestic responsibilities of top-research medical school graduates. PLoS One. 2022; 17(4):e0267288.
Domestic tethers: Gender differences in career paths and domestic responsibilities of top-research medical school graduates.
Kaplan TB, Gopal A, Block VJ, Suskind AM, Zhao C, Polgar-Turcsanyi M, Saraceno TJ, Gomez R, Santaniello A, Consortium S, Ayoubi NE, Cree BAC, Hauser SL, Weiner H, Chitnis T, Khoury S, Bove R
Challenges to Longitudinal Characterization of Lower Urinary Tract Dysfunction in Multiple Sclerosis. Mult Scler Relat Disord. 2022 Jun; 62:103793.
Challenges to Longitudinal Characterization of Lower Urinary Tract Dysfunction in Multiple Sclerosis.
Sharmin S, Malpas CB, Roos I, Diouf I, Alroughani R, Ozakbas S, Izquierdo G, Eichau S, Horakova D, Havrdova EK, Patti F, Terzi M, Boz C, Yamout B, Khoury SJ, Onofrj M, Lugaresi A, Altintas A, Prat A, Girard M, Duquette P, Sá MJ, La Spitaleri D, Sidhom Y, Gouider R, Mrabet S, Soysal A, Turkoglu R, Amato MP, Fragoso YD, Kalincik T
Journal of neurology, neurosurgery, and psychiatry
Early predictors of disability in paediatric multiple sclerosis: evidence from a multi-national registry. J Neurol Neurosurg Psychiatry. 2022 Sep 30.
Early predictors of disability in paediatric multiple sclerosis: evidence from a multi-national registry.
El Ayoubi NK, Sabbagh HM, Bou Rjeily N, Hannoun S, Khoury SJ
Rate of Retinal Layer Thinning as a Biomarker for Conversion to Progressive Disease in Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2022 11; 9(6).
Rate of Retinal Layer Thinning as a Biomarker for Conversion to Progressive Disease in Multiple Sclerosis.
Ayoubi NKE, Moussa H, Younes A, Haddad R, Khoury SJ
Use of retinal optical coherence tomography to differentiate suspected neuromyelitis optica spectrum disorder from multiple sclerosis: A cross-sectional study. Mult Scler Relat Disord. 2022 Dec; 68:104160.
Use of retinal optical coherence tomography to differentiate suspected neuromyelitis optica spectrum disorder from multiple sclerosis: A cross-sectional study.
Signori A, Lorscheider J, Vukusic S, Trojano M, Iaffaldano P, Hillert J, Hyde R, Pellegrini F, Magyari M, Koch-Henriksen N, Sørensen PS, Spelman T, van der Walt A, Horakova D, Havrdova E, Girard M, Eichau S, Grand'Maison F, Gerlach O, Terzi M, Ozakbas S, Skibina O, Van Pesch V, Sa MJ, Prevost J, Alroughani R, McCombe PA, Gouider R, Mrabet S, Castillo-Trivino T, Zhu C, de Gans K, Sánchez-Menoyo JL, Yamout B, Khoury S, Sormani MP, Kalincik T, Butzkueven H
Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network. J Neurol Neurosurg Psychiatry. 2023 01; 94(1):23-30.
Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network.
Zhu C, Zhou Z, Roos I, Merlo D, Kalincik T, Ozakbas S, Skibina O, Kuhle J, Hodgkinson S, Boz C, Alroughani R, Lechner-Scott J, Barnett M, Izquierdo G, Prat A, Horakova D, Kubala Havrdova E, Macdonell R, Patti F, Khoury SJ, Slee M, Karabudak R, Onofrj M, Van Pesch V, Prevost J, Monif M, Jokubaitis V, van der Walt A, Butzkueven H
Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2022 12; 93(12):1330-1337.
Comparing switch to ocrelizumab, cladribine or natalizumab after fingolimod treatment cessation in multiple sclerosis.
Roos I, Malpas C, Leray E, Casey R, Horakova D, Havrdova EK, Debouverie M, Patti F, De Seze J, Izquierdo G, Eichau S, Edan G, Prat A, Girard M, Ozakbas S, Grammond P, Zephir H, Ciron J, Maillart E, Moreau T, Amato MP, Labauge P, Alroughani R, Buzzard K, Skibina O, Terzi M, Laplaud DA, Berger E, Grand'Maison F, Lebrun-Frenay C, Cartechini E, Boz C, Lechner-Scott J, Clavelou P, Stankoff B, Prevost J, Kappos L, Pelletier J, Shaygannejad V, Yamout BI, Khoury SJ, Gerlach O, Spitaleri DLA, Van Pesch V, Gout O, Turkoglu R, Heinzlef O, Thouvenot E, McCombe PA, Soysal A, Bourre B, Slee M, Castillo-Trivino T, Bakchine S, Ampapa R, Butler EG, Wahab A, Macdonell RA, Aguera-Morales E, Cabre P, Ben NH, Van der Walt A, Laureys G, Van Hijfte L, Ramo-Tello CM, Maubeuge N, Hodgkinson S, Sánchez-Menoyo JL, Barnett MH, Labeyrie C, Vucic S, Sidhom Y, Gouider R, Csepany T, Sotoca J, de Gans K, Al-Asmi A, Fragoso YD, Vukusic S, Butzkueven H, Kalincik T
Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis. Neurology. 2022 10 25; 99(17):e1926-e1944.
Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis.
Moradi N, Sharmin S, Malpas CB, Shaygannejad V, Terzi M, Boz C, Yamout B, Khoury SJ, Turkoglu R, Karabudak R, Shalaby N, Soysal A, Altintas A, Inshasi J, Al-Harbi T, Alroughani R, Kalincik T
Multiple sclerosis (Houndmills, Basingstoke, England)
External validation of a clinical prediction model in multiple sclerosis. Mult Scler. 2023 02; 29(2):261-269.
External validation of a clinical prediction model in multiple sclerosis.
Chung C, Yang X, Bae T, Vong KI, Mittal S, Donkels C, Westley Phillips H, Li Z, Marsh APL, Breuss MW, Ball LL, Garcia CAB, George RD, Gu J, Xu M, Barrows C, James KN, Stanley V, Nidhiry AS, Khoury S, Howe G, Riley E, Xu X, Copeland B, Wang Y, Kim SH, Kang HC, Schulze-Bonhage A, Haas CA, Urbach H, Prinz M, Limbrick DD, Gurnett CA, Smyth MD, Sattar S, Nespeca M, Gonda DD, Imai K, Takahashi Y, Chen HH, Tsai JW, Conti V, Guerrini R, Devinsky O, Silva WA, Machado HR, Mathern GW, Abyzov A, Baldassari S, Baulac S, Gleeson JG
Comprehensive multi-omic profiling of somatic mutations in malformations of cortical development. Nat Genet. 2023 02; 55(2):209-220.
Comprehensive multi-omic profiling of somatic mutations in malformations of cortical development.
Dahham J, Hiligsmann M, Kremer I, Khoury SJ, Darwish H, Hosseini H, Evers S, Rizk R
The societal costs of multiple sclerosis in Lebanon: a cross-sectional study. Expert Rev Pharmacoecon Outcomes Res. 2023 Apr; 23(4):419-430.
The societal costs of multiple sclerosis in Lebanon: a cross-sectional study.
Daruwalla C, Shaygannejad V, Ozakbas S, Havrdova EK, Horakova D, Alroughani R, Boz C, Patti F, Onofrj M, Lugaresi A, Eichau S, Girard M, Prat A, Duquette P, Yamout B, Khoury SJ, Sajedi SA, Turkoglu R, Altintas A, Skibina O, Buzzard K, Grammond P, Karabudak R, van der Walt A, Butzkueven H, Maimone D, Lechner-Scott J, Soysal A, John N, Prevost J, Spitaleri D, Ramo-Tello C, Gerlach O, Iuliano G, Foschi M, Ampapa R, van Pesch V, Barnett M, Shalaby N, D'hooghe M, Kuhle J, Sa MJ, Fabis-Pedrini M, Kermode A, Mrabet S, Gouider R, Hodgkinson S, Laureys G, Van Hijfte L, Macdonell R, Oreja-Guevara C, Cristiano E, McCombe P, Sanchez-Menoyo JL, Singhal B, Blanco Y, Hughes S, Garber J, Solaro C, McGuigan C, Taylor B, de Gans K, Habek M, Al-Asmi A, Mihaela S, Castillo Triviño T, Al-Harbi T, Rojas JI, Gray O, Khurana D, Van Wijmeersch B, Grigoriadis N, Inshasi J, Oh J, Aguera-Morales E, Fragoso Y, Moore F, Shaw C, Baghbanian SM, Shuey N, Willekens B, Hardy TA, Decoo D, Sempere AP, Field D, Wynford-Thomas R, Cunniffe NG, Roos I, Malpas CB, Coles AJ, Kalincik T, Brown JWL
Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis. Mult Scler. 2023 06; 29(7):875-883.
Early non-disabling relapses are important predictors of disability accumulation in people with relapsing-remitting multiple sclerosis.
Bove R, Musallam A, Healy BC, Houtchens M, Glanz BI, Khoury S, Guttmann CR, De Jager PL, Chitnis T
No sex-specific difference in disease trajectory in multiple sclerosis patients before and after age 50. BMC Neurol. 2013 Jul 03; 13:73.
No sex-specific difference in disease trajectory in multiple sclerosis patients before and after age 50.
Chitnis T, Foley J, Ionete C, El Ayoubi NK, Saxena S, Gaitan-Walsh P, Lokhande H, Paul A, Saleh F, Weiner H, Qureshi F, Becich MJ, da Costa FR, Gehman VM, Zhang F, Keshavan A, Jalaleddini K, Ghoreyshi A, Khoury SJ
Clinical validation of a multi-protein, serum-based assay for disease activity assessments in multiple sclerosis. Clin Immunol. 2023 08; 253:109688.
Clinical validation of a multi-protein, serum-based assay for disease activity assessments in multiple sclerosis.
Khoury S, Cockett A, Aso Y, Chatelain C, Andersson L, Abrams P, Griffiths K, Denis L
International Consultation on Urological Diseases: a decade of progress. Prostate. 2000 Oct 01; 45(2):194-9.
International Consultation on Urological Diseases: a decade of progress.
Progress in clinical and biological research
Management of hormone resistant stage C and D prostatic cancer. Prog Clin Biol Res. 1987; 243B:513-20.
Management of hormone resistant stage C and D prostatic cancer.
Abou Mrad T, Naja K, Khoury SJ, Hannoun S
Central vein sign and paramagnetic rim sign: From radiologically isolated syndrome to multiple sclerosis. Eur J Neurol. 2023 09; 30(9):2912-2918.
Central vein sign and paramagnetic rim sign: From radiologically isolated syndrome to multiple sclerosis.
Future directions in the management of benign prostatic hyperplasia. Br J Urol. 1992 Nov; 70 Suppl 1:27-32.
Future directions in the management of benign prostatic hyperplasia.
Sharmin S, Roos I, Simpson-Yap S, Malpas C, Sánchez MM, Ozakbas S, Horakova D, Havrdova EK, Patti F, Alroughani R, Izquierdo G, Eichau S, Boz C, Zakaria M, Onofrj M, Lugaresi A, Weinstock-Guttman B, Prat A, Girard M, Duquette P, Terzi M, Amato MP, Karabudak R, Grand'Maison F, Khoury SJ, Grammond P, Lechner-Scott J, Buzzard K, Skibina O, van der Walt A, Butzkueven H, Turkoglu R, Altintas A, Maimone D, Kermode A, Shalaby N, Pesch VV, Butler E, Sidhom Y, Gouider R, Mrabet S, Gerlach O, Soysal A, Barnett M, Kuhle J, Hughes S, Sa MJ, Hodgkinson S, Oreja-Guevara C, Ampapa R, Petersen T, Ramo-Tello C, Spitaleri D, McCombe P, Taylor B, Prevost J, Foschi M, Slee M, McGuigan C, Laureys G, Hijfte LV, de Gans K, Solaro C, Oh J, Macdonell R, Aguera-Morales E, Singhal B, Gray O, Garber J, Wijmeersch BV, Simu M, Castillo-Triviño T, Sanchez-Menoyo JL, Khurana D, Al-Asmi A, Al-Harbi T, Deri N, Fragoso Y, Lalive PH, Sinnige LGF, Shaw C, Shuey N, Csepany T, Sempere AP, Moore F, Decoo D, Willekens B, Gobbi C, Massey J, Hardy T, Parratt J, Kalincik T
The risk of secondary progressive multiple sclerosis is geographically determined but modifiable. Brain. 2023 11 02; 146(11):4633-4644.
The risk of secondary progressive multiple sclerosis is geographically determined but modifiable.
Harding-Forrester S, Roos I, Nguyen AL, Malpas CB, Diouf I, Moradi N, Sharmin S, Izquierdo G, Eichau S, Patti F, Horakova D, Kubala Havrdova E, Prat A, Girard M, Duquette P, Grand'Maison F, Onofrj M, Lugaresi A, Grammond P, Ozakbas S, Amato MP, Gerlach O, Sola P, Ferraro D, Buzzard K, Skibina O, Lechner-Scott J, Alroughani R, Boz C, Van Pesch V, Cartechini E, Terzi M, Maimone D, Ramo-Tello C, Yamout B, Khoury SJ, La Spitaleri D, Sa MJ, Blanco Y, Granella F, Slee M, Butler E, Sidhom Y, Gouider R, Bergamaschi R, Karabudak R, Ampapa R, Sánchez-Menoyo JL, Prevost J, Castillo-Trivino T, McCombe PA, Macdonell R, Laureys G, Van Hijfte L, Oh J, Altintas A, de Gans K, Turkoglu R, van der Walt A, Butzkueven H, Vucic S, Barnett M, Cristiano E, Hodgkinson S, Iuliano G, Kappos L, Kuhle J, Shaygannejad V, Soysal A, Weinstock-Guttman B, Van Wijmeersch B, Kalincik T
Disability accrual in primary and secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2023 09; 94(9):707-717.
Disability accrual in primary and secondary progressive multiple sclerosis.
Zorina-Lichtenwalter K, Meloto CB, Khoury S, Diatchenko L
Genetic predictors of human chronic pain conditions. Neuroscience. 2016 Dec 03; 338:36-62.
Genetic predictors of human chronic pain conditions.
International consultation on benign prostatic hyperplasia. Prog Clin Biol Res. 1994; 386:617-24.
International consultation on benign prostatic hyperplasia.
Kalincik T, Sharmin S, Roos I, Freedman MS, Atkins H, Burman J, Massey J, Sutton I, Withers B, Macdonell R, Grigg A, Torkildsen Ø, Bo L, Lehmann AK, Havrdova EK, Krasulova E, Trnený M, Kozak T, van der Walt A, Butzkueven H, McCombe P, Skibina O, Lechner-Scott J, Willekens B, Cartechini E, Ozakbas S, Alroughani R, Kuhle J, Patti F, Duquette P, Lugaresi A, Khoury SJ, Slee M, Turkoglu R, Hodgkinson S, John N, Maimone D, Sa MJ, van Pesch V, Gerlach O, Laureys G, Van Hijfte L, Karabudak R, Spitaleri D, Csepany T, Gouider R, Castillo-Triviño T, Taylor B, Sharrack B, Snowden JA, Mrabet S, Garber J, Sanchez-Menoyo JL, Aguera-Morales E, Blanco Y, Al-Asmi A, Weinstock-Guttman B, Fragoso Y, de Gans K, Kermode A
Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis. JAMA Neurol. 2023 07 01; 80(7):702-713.
Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis.
Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie
[How to treat locally advanced and metastatic untreated cancer of the prostate?]. Prog Urol. 1996 Apr; 6(2 Suppl 1):42-5.
[How to treat locally advanced and metastatic untreated cancer of the prostate?].
Management of hormone resistant stage C and D prostatic cancer. Prog Clin Biol Res. 1989; 303:347-52.
[How to treat hormone-resistant prostatic cancer?]. Prog Urol. 1996 Apr; 6(2 Suppl 1):46-56.
[How to treat hormone-resistant prostatic cancer?].
Kraus D, Khoury S, Fendyur A, Kachalsky SG, Abu-Hatoum T, Rahamimoff R
Journal of basic and clinical physiology and pharmacology
Intracellular calcium dynamics--sparks of insight. J Basic Clin Physiol Pharmacol. 2000; 11(4):331-65.
Intracellular calcium dynamics--sparks of insight.
How to stage prostatic cancer in 1986. Prog Clin Biol Res. 1987; 243B:277-82.
Game X, Houlgatte A, Fournier R, Duhamel P, Baranger B, Khoury S
[Dedifferentiation of mature teratomas secondary to testicular cancer: report of 2 cases]. Prog Urol. 2001 Feb; 11(1):73-6; discussion 76-7.
[Dedifferentiation of mature teratomas secondary to testicular cancer: report of 2 cases].
Zhu C, Kalincik T, Horakova D, Zhou Z, Buzzard K, Skibina O, Alroughani R, Izquierdo G, Eichau S, Kuhle J, Patti F, Grand'Maison F, Hodgkinson S, Grammond P, Lechner-Scott J, Butler E, Prat A, Girard M, Duquette P, Macdonell RAL, Weinstock-Guttman B, Ozakbas S, Slee M, Sa MJ, Van Pesch V, Barnett M, Van Wijmeersch B, Gerlach O, Prevost J, Terzi M, Boz C, Laureys G, Van Hijfte L, Kermode AG, Garber J, Yamout B, Khoury SJ, Merlo D, Monif M, Jokubaitis V, van der Walt A, Butzkueven H
Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation. JAMA Neurol. 2023 07 01; 80(7):739-748.
Comparison Between Dimethyl Fumarate, Fingolimod, and Ocrelizumab After Natalizumab Cessation.
Duclos C, Dumont M, Wiseman-Hakes C, Arbour C, Mongrain V, Gaudreault PO, Khoury S, Lavigne G, Desautels A, Gosselin N
Sleep and wake disturbances following traumatic brain injury. Pathol Biol (Paris). 2014 Oct; 62(5):252-61.
Sleep and wake disturbances following traumatic brain injury.
Imitola J, Hollingsworth EW, Watanabe F, Olah M, Elyaman W, Starossom S, Kivisäkk P, Khoury SJ
Stat1 is an inducible transcriptional repressor of neural stem cells self-renewal program during neuroinflammation. Front Cell Neurosci. 2023; 17:1156802.
Stat1 is an inducible transcriptional repressor of neural stem cells self-renewal program during neuroinflammation.
Li Y, Saul A, Taylor B, Ponsonby AL, Simpson-Yap S, Blizzard L, Broadley S, Lechner-Scott J, Karabudak R, Patti F, Eichau S, Onofrj M, Ozakbas S, Horakova D, Kubala Havrdova E, Grand'Maison F, Alroughani R, Gerlach O, Amato MP, Altintas A, Girard M, Duquette P, Blanco Y, Ramo-Tello C, Laureys G, Kalincik T, Khoury SJ, Shaygannejad V, Etemadifar M, Singhal B, Mrabet S, Foschi M, Habek M, John N, Hughes S, McCombe P, Ampapa R, van der Walt A, Butzkueven H, de Gans K, McGuigan C, Oreja-Guevara C, Sa MJ, Petersen T, Al-Harbi T, Sempere AP, Van Wijmeersch B, Grigoriadis N, Prevost J, Gray O, Castillo-Triviño T, Macdonell R, Lugaresi A, Sajedi SA, van der Mei I
Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies. J Neurol. 2024 Jan; 271(1):472-485.
Examining the environmental risk factors of progressive-onset and relapsing-onset multiple sclerosis: recruitment challenges, potential bias, and statistical strategies.
Yaktine N, Fares S, Khoury SJ, Darwish H
Psychometric validation of the Arabic multiple sclerosis resiliency scale: Uncovering resilience factors in Lebanese MS patients for clinical and research advancements. eNeurologicalSci. 2024 Mar; 34:100489.
Psychometric validation of the Arabic multiple sclerosis resiliency scale: Uncovering resilience factors in Lebanese MS patients for clinical and research advancements.
Spelman T, Magyari M, Butzkueven H, Van Der Walt A, Vukusic S, Trojano M, Iaffaldano P, Horáková D, Drahota J, Pellegrini F, Hyde R, Duquette P, Lechner-Scott J, Sajedi SA, Lalive P, Shaygannejad V, Ozakbas S, Eichau S, Alroughani R, Terzi M, Girard M, Kalincik T, Grand'Maison F, Skibina O, Khoury SJ, Yamout B, Sa MJ, Gerlach O, Blanco Y, Karabudak R, Oreja-Guevara C, Altintas A, Hughes S, McCombe P, Ampapa R, de Gans K, McGuigan C, Soysal A, Prevost J, John N, Inshasi J, Stawiarz L, Manouchehrinia A, Forsberg L, Sellebjerg F, Glaser A, Pontieri L, Joensen H, Rasmussen PV, Sejbaek T, Poulsen MB, Christensen JR, Kant M, Stilund M, Mathiesen H, Hillert J
Predictors of treatment switching in the Big Multiple Sclerosis Data Network. Front Neurol. 2023; 14:1274194.
Predictors of treatment switching in the Big Multiple Sclerosis Data Network.
Signori A, Ponzano M, Kalincik T, Ozakbas S, Horakova D, Kubala Havrdova E, Alroughani R, Patti F, Kuhle J, Izquierdo G, Eichau S, Yamout B, Khoury SJ, Karabudak R, Grammond P, Duquette P, Roos I, Butzkueven H, van der Walt A, Sormani MP
Emulating randomised clinical trials in relapsing-remitting multiple sclerosis with non-randomised real-world evidence: an application using data from the MSBase Registry. J Neurol Neurosurg Psychiatry. 2024 Jun 17; 95(7):620-625.
Emulating randomised clinical trials in relapsing-remitting multiple sclerosis with non-randomised real-world evidence: an application using data from the MSBase Registry.
Yamout B, Al-Jumah M, Sahraian MA, Almalik Y, Khaburi JA, Shalaby N, Aljarallah S, Bohlega S, Dahdaleh M, Almahdawi A, Khoury SJ, Koussa S, Slassi E, Daoudi S, Aref H, Mrabet S, Zeineddine M, Zakaria M, Inshasi J, Gouider R, Alroughani R
Consensus recommendations for diagnosis and treatment of Multiple Sclerosis: 2023 revision of the MENACTRIMS guidelines. Mult Scler Relat Disord. 2024 Mar; 83:105435.
Consensus recommendations for diagnosis and treatment of Multiple Sclerosis: 2023 revision of the MENACTRIMS guidelines.
Spelman T, Simoneau G, Hyde R, Kuhelj R, Alroughani R, Ozakbas S, Karabudak R, Yamout BI, Khoury SJ, Terzi M, Boz C, Horakova D, Kubala Havrdova E, Weinstock-Guttman B, Patti F, Altintas A, Mrabet S, Gouider R, Inshasi J, Shaygannejad V, Eichau S, Ward WL, Butzkueven H
Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis: A Registry-Based Study. Neurology. 2024 04 09; 102(7):e208114.
Comparative Effectiveness of Natalizumab, Fingolimod, and Injectable Therapies in Pediatric-Onset Multiple Sclerosis: A Registry-Based Study.
Chowdhury R, Khoury S, Leroux J, Alsayegh R, Lawlor CM, Graham ME
Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine
Alternative Therapies for Ankyloglossia-Associated Breastfeeding Challenges: A Systematic Review. Breastfeed Med. 2024 Jul; 19(7):497-504.
Alternative Therapies for Ankyloglossia-Associated Breastfeeding Challenges: A Systematic Review.
Dekeyser C, Hautekeete M, Cambron M, Van Pesch V, Patti F, Kuhle J, Khoury S, Lechner Scott J, Gerlach O, Lugaresi A, Maimone D, Surcinelli A, Grammond P, Kalincik T, Habek M, Willekens B, Macdonell R, Lalive P, Csepany T, Butzkueven H, Boz C, Tomassini V, Foschi M, Sánchez-Menoyo JL, Altintas A, Mrabet S, Iuliano G, Sa MJ, Alroughani R, Karabudak R, Aguera-Morales E, Gray O, de Gans K, van der Walt A, McCombe PA, Deri N, Garber J, Al-Asmi A, Skibina O, Duquette P, Cartechini E, Spitaleri D, Gouider R, Soysal A, Van Hijfte L, Slee M, Amato MP, Buzzard K, Laureys G
Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort study. J Neurol Neurosurg Psychiatry. 2024 Oct 16; 95(11):1021-1031.
Routine CSF parameters as predictors of disease course in multiple sclerosis: an MSBase cohort study.
Dahham J, Hiligsmann M, Kremer I, Khoury SJ, Darwish H, Hosseini H, Hallit S, Evers S, Rizk R
Health-related quality of life and utilities among Lebanese patients with Multiple Sclerosis: A cross-sectional study. Mult Scler Relat Disord. 2024 Jun; 86:105635.
Health-related quality of life and utilities among Lebanese patients with Multiple Sclerosis: A cross-sectional study.
Spelman T, Eichau S, Alroughani R, Ozakbas S, Khoury SJ, Patti F, Kubala Havrdova E, Boz C, Terzi M, Kuhle J, Grammond P, Lechner-Scott J, Gray O, Amato MP, Laureys G, Shaygannejad V, Hyde R, Wang H, Bozin I, Belviso N, Quan C, Zeng F, van der Walt A, Butzkueven H
Comparative effectiveness of dimethyl fumarate versus non-specific immunosuppressants: Real-world evidence from MSBase. Mult Scler J Exp Transl Clin. 2024 Apr-Jun; 10(2):20552173241247182.
Comparative effectiveness of dimethyl fumarate versus non-specific immunosuppressants: Real-world evidence from MSBase.
Lal AP, Foong YC, Sanfilippo PG, Spelman T, Rath L, Levitz D, Fabis-Pedrini M, Foschi M, Habek M, Kalincik T, Roos I, Lechner-Scott J, John N, Soysal A, D'Amico E, Gouider R, Mrabet S, Gross-Paju K, Cárdenas-Robledo S, Moghadasi AN, Sa MJ, Gray O, Oh J, Reddel S, Ramanathan S, Al-Harbi T, Altintas A, Hardy TA, Ozakbas S, Alroughani R, Kermode AG, Surcinelli A, Laureys G, Eichau S, Prat A, Girard M, Duquette P, Hodgkinson S, Ramo-Tello C, Maimone D, McCombe P, Spitaleri D, Sanchez-Menoyo JL, Yetkin MF, Baghbanian SM, Karabudak R, Al-Asmi A, Jakob GB, Khoury SJ, Etemadifar M, van Pesch V, Buzzard K, Taylor B, Butzkueven H, Van der Walt A
A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic. J Neurol. 2024 Sep; 271(9):5813-5824.
A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic.
Roos I, Sharmin S, Malpas C, Ozakbas S, Lechner-Scott J, Hodgkinson S, Alroughani R, Eichau Madueño S, Boz C, van der Walt A, Butzkueven H, Buzzard K, Skibina O, Foschi M, Grand'Maison F, John N, Grammond P, Terzi M, Prévost J, Barnett M, Laureys G, Van Hijfte L, Luis Sanchez-Menoyo J, Blanco Y, Oh J, McCombe P, Ramo Tello C, Soysal A, Prat A, Duquette P, Yamout BI, Khoury S, van Pesch V, Macdonell R, José Sá M, Slee M, Kuhle J, Maimone D, Spitaleri D, Willekens B, Asmi AA, Tallantyre E, Robertson NP, Coles A, L Brown JW, Kalincik T
Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis. Mult Scler. 2024 Aug; 30(9):1163-1175.
Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis.
Zeineddine M, Al-Roughani R, Farouk Ahmed S, Khoury S, El-Ayoubi N, Al-Mahdawi A, Al-Khabouri J, Al-Asmi A, Chentouf A, Inshasi J, Gouider R, Mrabet S, Shalaby N, Massouh J, Mohamed Ramzy Hasan Mohamed F, Al-Hajje A, Salameh P, Dimassi H, Boumediene F, Yamout B
Safety and effectiveness of disease-modifying therapies after switching from natalizumab. Mult Scler. 2024 Jul; 30(8):1026-1035.
Safety and effectiveness of disease-modifying therapies after switching from natalizumab.
Khoury S, Zabihi-Pour D, Davidson J, Poolacherla R, Nair G, Biswas A, You P, Strychowsky JE
Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale
The Safety of the Laryngeal Mask Airway in Adenotonsillectomy: A Systematic Review and Meta-Analysis. J Otolaryngol Head Neck Surg. 2024 Jan-Dec; 53:19160216241263851.
The Safety of the Laryngeal Mask Airway in Adenotonsillectomy: A Systematic Review and Meta-Analysis.
El Ayoubi NK, Ismail A, Fahd F, Younes L, Chakra NA, Khoury SJ
Annals of clinical and translational neurology
Retinal optical coherence tomography measures in multiple sclerosis: a systematic review and meta-analysis. Ann Clin Transl Neurol. 2024 Sep; 11(9):2236-2253.
Retinal optical coherence tomography measures in multiple sclerosis: a systematic review and meta-analysis.
De Brouwer E, Becker T, Werthen-Brabants L, Dewulf P, Iliadis D, Dekeyser C, Laureys G, Van Wijmeersch B, Popescu V, Dhaene T, Deschrijver D, Waegeman W, De Baets B, Stock M, Horakova D, Patti F, Izquierdo G, Eichau S, Girard M, Prat A, Lugaresi A, Grammond P, Kalincik T, Alroughani R, Grand'Maison F, Skibina O, Terzi M, Lechner-Scott J, Gerlach O, Khoury SJ, Cartechini E, Van Pesch V, Sà MJ, Weinstock-Guttman B, Blanco Y, Ampapa R, Spitaleri D, Solaro C, Maimone D, Soysal A, Iuliano G, Gouider R, Castillo-Triviño T, Sánchez-Menoyo JL, Laureys G, van der Walt A, Oh J, Aguera-Morales E, Altintas A, Al-Asmi A, de Gans K, Fragoso Y, Csepany T, Hodgkinson S, Deri N, Al-Harbi T, Taylor B, Gray O, Lalive P, Rozsa C, McGuigan C, Kermode A, Sempere AP, Mihaela S, Simo M, Hardy T, Decoo D, Hughes S, Grigoriadis N, Sas A, Vella N, Moreau Y, Peeters L
Machine-learning-based prediction of disability progression in multiple sclerosis: An observational, international, multi-center study. PLOS Digit Health. 2024 Jul; 3(7):e0000533.
Machine-learning-based prediction of disability progression in multiple sclerosis: An observational, international, multi-center study.
Siriratnam P, Sanfilippo P, van der Walt A, Sharmin S, Foong YC, Yeh WZ, Zhu C, Khoury SJ, Csepany T, Willekens B, Etemadifar M, Ozakbas S, Nytrova P, Altintas A, Al-Asmi A, Yamout B, Laureys G, Patti F, Simo M, Surcinelli A, Foschi M, McCombe PA, Alroughani R, Sánchez-Menoyo JL, Turkoglu R, Soysal A, Lechner Scott J, Kalincik T, Butzkueven H, Jokubaitis V, Huda S, Monif M
Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study. J Neurol Neurosurg Psychiatry. 2025 Mar 24; 96(4):361-369.
Predictors of relapse risk and treatment response in AQP4-IgG positive and seronegative NMOSD: A multicentre study.
Kreiter D, Kalincik T, Hupperts R, Patti F, Spitaleri D, Foschi M, Surcinelli A, Maimone D, Yamout B, Khoury SJ, Lechner-Scott J, Ozakbas S, Gerlach O
Effectiveness of Disease-Modifying Treatment on Spinal Cord Lesion Formation in Relapse-Onset Multiple Sclerosis: An MSBase Registry Study. CNS Drugs. 2024 Nov; 38(11):921-930.
Effectiveness of Disease-Modifying Treatment on Spinal Cord Lesion Formation in Relapse-Onset Multiple Sclerosis: An MSBase Registry Study.
Zhu B, Buttrick T, Bassil R, Zhu C, Olah M, Wu C, Xiao S, Orent W, Elyaman W, Khoury SJ
IL-4 and retinoic acid synergistically induce regulatory dendritic cells expressing Aldh1a2. J Immunol. 2013 Sep 15; 191(6):3139-51.
IL-4 and retinoic acid synergistically induce regulatory dendritic cells expressing Aldh1a2.
Siriratnam P, Huda S, Van Der Walt A, Sanfilippo PG, Sharmin S, Foong YC, Yeh WZ, Zhu C, Khoury SJ, Csepany T, Willekens B, Etemadifar M, Ozakbas S, Nytrova P, Altintas A, Al-Asmi A, Ramo-Tello CM, Laureys G, Patti F, Horakova D, Foschi M, Boz C, Mccombe PA, Turkoglu R, Lechner-Scott J, Roos I, Kalincik T, Jokubaitis VG, Butzkueven H, Monif M
Prevalence of Progression Independent of Relapse Activity and Relapse-Associated Worsening in Patients With AQP4-IgG-Positive NMOSD. Neurology. 2024 12 24; 103(12):e209940.
Prevalence of Progression Independent of Relapse Activity and Relapse-Associated Worsening in Patients With AQP4-IgG-Positive NMOSD.
Machtoub D, Fares C, Sinan H, Al Hariri M, Nehme R, Chami J, Joukhdar R, Tcheroyan R, Adib S, Khoury SJ
Factors affecting fatigue progression in multiple sclerosis patients. Sci Rep. 2024 12 30; 14(1):31682.
Factors affecting fatigue progression in multiple sclerosis patients.
Sex influences in autoimmune disease. Clin Immunol. 2013 Nov; 149(2):169.
D'hondt R, Dedja K, Aerts S, Van Wijmeersch B, Kalincik T, Reddel S, Havrdova EK, Lugaresi A, Weinstock-Guttman B, Mrabet S, Lalive P, Kermode AG, Ozakbas S, Patti F, Prat A, Tomassini V, Roos I, Alroughani R, Gerlach O, Khoury SJ, van Pesch V, Sá MJ, Prevost J, Spitaleri D, McCombe P, Solaro C, van der Walt A, Butzkueven H, Laureys G, Sánchez-Menoyo JL, de Gans K, Al-Asmi A, Deri N, Csepany T, Al-Harbi T, Carroll WM, Rozsa C, Singhal B, Hardy TA, Ramanathan S, Peeters L, Vens C
Computer methods and programs in biomedicine
Explainable time-to-progression predictions in multiple sclerosis. Comput Methods Programs Biomed. 2025 May; 263:108624.
Explainable time-to-progression predictions in multiple sclerosis.
Toscano S, Spelman T, Ozakbas S, Alroughani R, Chisari CG, Lo Fermo S, Prat A, Girard M, Duquette P, Izquierdo G, Eichau S, Grammond P, Boz C, Kalincik T, Blanco Y, Buzzard K, Skibina O, Sa MJ, van der Walt A, Butzkueven H, Terzi M, Gerlach O, Grand'Maison F, Foschi M, Surcinelli A, Barnett M, Lugaresi A, Onofrj M, Yamout B, Khoury SJ, Prevost J, Lechner-Scott J, Maimone D, Amato MP, Spitaleri D, Van Pesch V, Macdonell R, Cartechini E, de Gans K, Slee M, Castillo-Triviño T, Soysal A, Sanchez-Menoyo JL, Laureys G, Van Hijfte L, McCombe P, Altintas A, Weinstock-Guttman B, Aguera-Morales E, Etemadifar M, Ramo-Tello C, John N, Turkoglu R, Hodgkinson S, Besora S, Van Wijmeersch B, Fernandez-Bolaños R, Patti F
First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis. Neurotherapeutics. 2025 Mar; 22(2):e00552.
First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis.
Müller J, Sharmin S, Lorscheider J, Horakova D, Kubala Havrdova E, Eichau S, Patti F, Grammond P, Buzzard K, Skibina O, Prat A, Girard M, Grand'Maison F, Alroughani R, Lechner-Scott J, Spitaleri D, Barnett M, Cartechini E, Sa MJ, Gerlach O, van der Walt A, Butzkueven H, Prevost J, Castillo-Triviño T, Yamout B, Khoury SJ, Yaldizli Ö, Derfuss T, Granziera C, Kuhle J, Kappos L, Roos I, Kalincik T
Treatment De-escalation in Relapsing-Remitting Multiple Sclerosis: An Observational Study. CNS Drugs. 2025 Apr; 39(4):403-416.
Treatment De-escalation in Relapsing-Remitting Multiple Sclerosis: An Observational Study.
Messina S, Vargas-Lowy D, Musallam A, Healy BC, Kivisakk P, Gandhi R, Bove R, Gholipour T, Khoury S, Weiner HL, Chitnis T
Increased leptin and A-FABP levels in relapsing and progressive forms of MS. BMC Neurol. 2013 Nov 11; 13:172.
Increased leptin and A-FABP levels in relapsing and progressive forms of MS.
Kivisäkk P, Healy BC, Francois K, Gandhi R, Gholipour T, Egorova S, Sevdalinova V, Quintana F, Chitnis T, Weiner HL, Khoury SJ
Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development. Mult Scler. 2014 Apr; 20(4):438-44.
Evaluation of circulating osteopontin levels in an unselected cohort of patients with multiple sclerosis: relevance for biomarker development.
Ottoboni L, Frohlich IY, Lee M, Healy BC, Keenan BT, Xia Z, Chitnis T, Guttmann CR, Khoury SJ, Weiner HL, Hafler DA, De Jager PL
Clinical relevance and functional consequences of the TNFRSF1A multiple sclerosis locus. Neurology. 2013 Nov 26; 81(22):1891-9.
Clinical relevance and functional consequences of the TNFRSF1A multiple sclerosis locus.
Müller J, Sharmin S, Lorscheider J, Ozakbas S, Karabudak R, Horakova D, Weinstock-Guttman B, Shaygannejad V, Etemadifar M, Alroughani R, Patti F, Eichau S, Prat A, Lugaresi A, Tomassini V, Kermode AG, Amato MP, Turkoglu R, Altintas A, Buzzard K, Soysal A, van der Walt A, Butzkueven H, Blanco Y, Gerlach O, Khoury SJ, Barnett M, John N, Lechner-Scott J, Foschi M, Surcinelli A, van Pesch V, Prevost J, Sa MJ, Maimone D, D'hooghe M, Hughes S, Hodgkinson S, McGuigan C, Cartechini E, Taylor B, Spitaleri D, Slee M, McCombe P, Yamout B, Benkert P, Kuhle J, Kappos L, Roos I, Kalincik T, Havrdova EK, Girard M, Duquette P, Fabis-Pedrini M, Carroll WM, Skibina O, Gouider R, Mrabet S, Ramo-Tello C, Solaro C, Habek M, Van Wijmeersch B, Ampapa R, Macdonell R, Oreja-Guevara C, de Gans K, Laureys G, Oh J, Garber J, Gray O, Agüera-Morales E, Sanchez-Menoyo JL, Castillo-Triviño T, Grigoriadis N, Petersen T, Hardy TA, Vucic S, Reddel S, Ramanathan S, Al-Asmi A, Simu M, Baghbanian SM, Poehlau D, Al-Harbi T, Rojas JI, Deri N, Lalive P, Cambron M, Csepany T, Shuey N, Willekens B, Shaw C, Decoo D, Massey J, Yaldizli Ö, Derfuss T, Granziera C
Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis. JAMA Neurol. 2025 Jun 01; 82(6):614-625.
Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis.
Siriratnam P, Huda S, Van der Walt A, Sanfilippo P, Sharmin S, Foong YC, Yeh WZ, Zhu C, Khoury SJ, Csepany T, Willekens B, Etemadifar M, Ozakbas S, Nytrova P, Altintas A, Al-Asmi A, Ramo-Tello C, Laureys G, Patti F, Horakova D, Foschi M, Boz C, McCombe P, Turkoglu R, Roos I, Lechner-Scott J, Kalincik T, Jokubaitis V, Butzkueven H, Monif M
Progression independent of relapse activity and relapse-associated worsening in seronegative NMOSD: an international cohort study. J Neurol. 2025 Apr 14; 272(5):339.
Progression independent of relapse activity and relapse-associated worsening in seronegative NMOSD: an international cohort study.
El Ayoubi NK, Bal MN, Metri N, El Sammak S, Baalbaki M, Gharios M, Fatfat A, Khoury SJ
Slower retinal thinning over a year predicts continuous NEDA status at follow-up in multiple sclerosis: A longitudinal OCT study. Mult Scler. 2025 Jun; 31(7):782-792.
Slower retinal thinning over a year predicts continuous NEDA status at follow-up in multiple sclerosis: A longitudinal OCT study.
El Ayoubi NK, Ismail A, Sader G, Abi Chakra N, El Ahdab J, Abboud J, Khoury SJ
Retinal Optical Coherence Tomography Longitudinal Measures as Prognostic Biomarkers in Multiple Sclerosis: Systematic Review and Meta-Analysis. Neurol Neuroimmunol Neuroinflamm. 2025 Jul; 12(4):e200416.
Retinal Optical Coherence Tomography Longitudinal Measures as Prognostic Biomarkers in Multiple Sclerosis: Systematic Review and Meta-Analysis.
Evaluation and treatment of lower urinary tract symptoms in older men. J Urol. 2013 Jan; 189(1 Suppl):S93-S101.
Frenay M, Giroux B, Khoury S, Derlon JM, Namer M
European journal of cancer (Oxford, England : 1990)
Phase II study of fotemustine in recurrent supratentorial malignant gliomas. Eur J Cancer. 1991; 27(7):852-6.
Phase II study of fotemustine in recurrent supratentorial malignant gliomas.
Yamout B, El-Salem K, Gebeily S, Khoury S, Abu Zeid N, Hamoulila K, Alhalabi MS, Hasan ZN, Al Hamadani H, Hamoodi H, Al Omar A, Dahdaleh M
The International journal of neuroscience
Multiple sclerosis in the Levant: a regional consensus statement. Int J Neurosci. 2014 May; 124(5):377-82.
Multiple sclerosis in the Levant: a regional consensus statement.
Hannoun S, Fayad G, El Ayoubi NK, Khoury SJ
The effect of lesion filling on brain age estimation in multiple sclerosis. BMC Med Imaging. 2025 Aug 27; 25(1):356.
The effect of lesion filling on brain age estimation in multiple sclerosis.
Predictors of Radiological and Clinical Disease Reactivation in Multiple Sclerosis Patients After Cessation of Natalizumab (Tysabri). Brain Behav. 2025 Sep; 15(9):e70904.
Predictors of Radiological and Clinical Disease Reactivation in Multiple Sclerosis Patients After Cessation of Natalizumab (Tysabri).
Fissolo N, Schaedelin S, Villar LM, Lünemann JD, Correale J, Rejdak K, Schwab N, Vilaseca A, Held F, García-Merino A, Bittner S, Trojano M, Furlan R, Tumani H, Pérez-Miralles F, Rosenstein I, Galimberti D, Álvarez-Bravo G, Thouvenot E, Llufriu S, Khoury SJ, Hoepner R, Martínez-Yélamos S, Hegen H, Drulovic J, Téllez-Lara N, Khalil M, Oechtering J, Pérez-Sempere Á, Rodríguez-Antigüedad A, Enrique-Martínez J, Strijbis E, Killestein J, Eichau S, Colombo E, Schaller-Nagengast J, Midaglia L, Sánchez-López AJ, Monreal E, Chan A, Paul F, Rovira À, Tintoré M, Lycke J, Zipp F, Hemmer B, Kuhle J, Montalban X, Comabella M
Prognostic Factors for Multiple Sclerosis Symptoms in Radiologically Isolated Syndrome. JAMA Neurol. 2025 07 01; 82(7):722-733.
Prognostic Factors for Multiple Sclerosis Symptoms in Radiologically Isolated Syndrome.
Pirmani A, De Brouwer E, Arany Á, Oldenhof M, Passemiers A, Faes A, Kalincik T, Ozakbas S, Gouider R, Willekens B, Horakova D, Havrdova EK, Patti F, Prat A, Lugaresi A, Tomassini V, Grammond P, Cartechini E, Roos I, Boz C, Alroughani R, Amato MP, Buzzard K, Lechner-Scott J, Guimarães J, Solaro C, Gerlach O, Soysal A, Kuhle J, Sanchez-Menoyo JL, Spitaleri D, Csepany T, Van Wijmeersch B, Ampapa R, Prevost J, Khoury SJ, Van Pesch V, John N, Maimone D, Weinstock-Guttman B, Laureys G, McCombe P, Blanco Y, Altintas A, Al-Asmi A, Garber J, Van der Walt A, Butzkueven H, de Gans K, Rozsa C, Taylor B, Al-Harbi T, Sas A, Rajda C, Gray O, Decoo D, Carroll WM, Kermode AG, Fabis-Pedrini M, Mason D, Perez-Sempere A, Simu M, Shuey N, Singhal B, Cauchi M, Hardy TA, Ramanathan S, Lalive P, Sirbu CA, Hughes S, Castillo Trivino T, Peeters LM, Moreau Y
Personalized federated learning for predicting disability progression in multiple sclerosis using real-world routine clinical data. NPJ Digit Med. 2025 Jul 24; 8(1):478.
Personalized federated learning for predicting disability progression in multiple sclerosis using real-world routine clinical data.
Zhu C, Zhou Z, Kalincik T, Roos I, Buzzard K, Skibina O, Alroughani R, Kuhle J, Girard M, Grammond P, Lechner-Scott J, Gerlach O, John N, McCombe P, Macdonell R, van Pesch V, Laureys G, Prevost J, Horakova D, Kubala Havrdova E, Castillo-Triviño T, Ramo-Tello C, Blanco Y, Meca-Lallana JE, Lugaresi A, Tomassini V, Cartechini E, Amato MP, Spitaleri D, Patti F, Maimone D, Foschi M, Surcinelli A, D'Amico E, Yamout B, Khoury SJ, Jose Sa M, Boz C, Ozakbas S, Weinstock-Guttman B, Merlo D, Monif M, Jokubaitis VG, van der Walt A, Butzkueven H
Persistent progression independent of relapse activity in multiple sclerosis. Brain Commun. 2025; 7(5):fcaf306.
Persistent progression independent of relapse activity in multiple sclerosis.
E-health literacy levels of multiple sclerosis patients in Lebanon. PLoS One. 2025; 20(10):e0335084.
E-health literacy levels of multiple sclerosis patients in Lebanon.
Foong YC, Merlo D, Gresle M, Buzzard K, Horakova D, Havrdova EK, Kalincik T, Roos I, Hodgkinson S, Lechner-Scott J, Lugaresi A, Weinstock-Guttman B, Ozakbas S, Surcinelli A, Foschi M, Boz C, Khoury SJ, Yamout B, Laureys G, Blanco Y, Skibina O, Kuhle J, John N, Alroughani R, Prevost J, Van Pesch V, Tomassini V, Prat A, Girard M, Terzi M, Shaygannejad V, Ampapa R, Gray O, Etemadifar M, Guimarães J, McCombe PA, Gerlach O, Solaro C, Butzkueven H, Zhu C, van der Walt A, Study Group M
Moderate-high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosis. J Neurol Neurosurg Psychiatry. 2025 Dec 12; 97(1):50-58.
Moderate-high efficacy disease-modifying therapies reduce relapse risk in late-onset multiple sclerosis.
Saba ES, Mrad MF, Nakib L, Dermesrobian V, Abboud J, Khoury SJ
Exosomal pHERV-W ENV as a dynamic biomarker for relapse prediction and prognosis in multiple sclerosis. J Neuroinflammation. 2025 Oct 21; 22(1):238.
Exosomal pHERV-W ENV as a dynamic biomarker for relapse prediction and prognosis in multiple sclerosis.
Lizak N, Sharmin S, Horáková D, Havrdova EK, Eichau S, van der Walt A, Butzkueven H, Lechner-Scott J, Buzzard K, Skibina O, Gerlach O, Prat A, Girard M, Duquette P, Alroughani R, Patti F, Grand'Maison F, Sá MJ, Aguera-Morales E, Hodgkinson S, Grammond P, Kuhle J, Yamout B, Khoury SJ, Ozakbas S, Csepany T, John N, Laureys G, Terzi M, Amato MP, Boz C, Al-Asmi A, Cartechini E, Gouider R, Mrabet S, Roos I, Kalincik T
Managing reactivation of multiple sclerosis during treatment with natalizumab. Mult Scler. 2026 Jan; 32(1):121-133.
Managing reactivation of multiple sclerosis during treatment with natalizumab.
Souissi A, Patti F, Spelman T, Chisari C, Gargouri A, John N, Kermode AG, Kalincik T, Butzkueven H, Sajedi SA, Lechner-Scott J, Roos I, Laureys G, Taylor B, Alroughani R, Khoury SJ, Macdonell R, Weinstock-Guttman B, Havrdova EK, Maimone D, Reddel S, Fabis-Pedrini M, Willekens B, Moghadasi AN, Lalive P, Lugaresi A, Ozakbas S, Solaro C, Cárdenas-Robledo S, Shaygannejad V, Etemadifar M, Boz C, Eichau S, Tomassini V, Terzi M, Prat A, Habek M, Blanco Y, Altintas A, Gerlach O, Turkoglu R, Buzzard K, Skibina O, Soysal A, van der Walt A, Hughes S, van Pesch V, Foschi M, Surcinelli A, Prevost J, Ramo-Tello C, McGuigan C, Sa MJ, Kuhle J, Spitaleri D, Singhal B, Ampapa R, de Gans K, Petersen T, Simu M, Lapointe E, Sanchez-Menoyo JL, Gray O, Garber J, Aguera-Morales E, Gross-Paju K, Castillo-Triviño T, Al-Asmi A, Grigoriadis N, Inshasi J, Al-Harbi T, Hardy TA, Ramanathan S, Cambron M, Shuey N, Sempere AP, Csepany T, Treviño-Frenk I, Rozsa C, Cauchi M, Karabudak R, Mrabet S, Gouider R
Effect of late-onset on multiple sclerosis phenotype and outcome: evidence from a multi-national registry. J Neurol. 2026 Feb 04; 273(2):114.
Effect of late-onset on multiple sclerosis phenotype and outcome: evidence from a multi-national registry.
Pilotte J, Huang AS, Khoury S, Zhang X, Tafreshi A, Vanderklish P, Sarraf ST, Pulido JS, Milman T
Translational vision science & technology
Detection of TTR Amyloid in the Conjunctiva Using a Novel Fluorescent Ocular Tracer. Transl Vis Sci Technol. 2024 02 01; 13(2):11.
Detection of TTR Amyloid in the Conjunctiva Using a Novel Fluorescent Ocular Tracer.
Venugopal N, Neposlan J, Bysice A, Khoury S, Madou E, Lee R, Strychowsky JE, St-Laurent A, Lawlor CM, Graham ME
Is Ankyloglossia Correlated With Pediatric Sleep Disordered Breathing? A Systematic Review. Laryngoscope. 2026 Mar; 136(3):1088-1098.
Is Ankyloglossia Correlated With Pediatric Sleep Disordered Breathing? A Systematic Review.
Roberts JI, Sharmin S, Horakova D, Kubala Havrdova E, Ozakbas S, Lugaresi A, Tomassini V, Alroughani R, Buzzard K, Skibina O, Boz C, Turkoglu R, Maimone D, Yamout B, Khoury SJ, Spitaleri D, Lechner-Scott J, Girard M, Duquette P, Al-Asmi A, Ampapa R, Foschi M, Surcinelli A, Patti F, Van Pesch V, Ramo-Tello C, Sánchez-Menoyo JL, Altintas A, Grammond P, Cartechini E, Csepany T, Laureys G, Willekens B, Roos I, Kalincik T, Study Group M
Corticosteroid treatment of multiple sclerosis relapses is associated with lower disability worsening over 5 years. J Neurol Neurosurg Psychiatry. 2025 Nov 13; 96(12):1185-1193.
Corticosteroid treatment of multiple sclerosis relapses is associated with lower disability worsening over 5 years.
Yamout B, Alroughani R, Mohamed SFA, Al-Mahdawi AM, Khoury SJ, El Ayoubi N, Inshasi J, Alkhaboori J, Al-Asmi A, Gouider R, Aljarallah S, Alkhawajah N, Al Malik Y, Abulaban A, Makkawi S, Khojah O, El-Hajj T, Massouh J, AlSalamat H, Dimassi H, Al-Hajje A, Salameh P, Boumediene F, Zeineddine M
Comparative effectiveness of natalizumab and anti-CD20 monoclonal antibodies in relapsing-remitting multiple sclerosis: a real-world propensity-score matched study. J Neurol Neurosurg Psychiatry. 2026 Apr 15; 97(5):398-404.
Comparative effectiveness of natalizumab and anti-CD20 monoclonal antibodies in relapsing-remitting multiple sclerosis: a real-world propensity-score matched study.
El Ayoubi NK, Fahd F, Tamim H, Hannoun S, Bal M, El-Hallak E, Khoury SJ
Comparative Effect of Standard Versus Extended Interval Dosing of Rituximab or Ocrelizumab in Multiple Sclerosis. Ann Clin Transl Neurol. 2025 Oct; 12(10):2086-2096.
Comparative Effect of Standard Versus Extended Interval Dosing of Rituximab or Ocrelizumab in Multiple Sclerosis.
Bassil R, Orent W, Olah M, Kurdi AT, Frangieh M, Buttrick T, Khoury SJ, Elyaman W
BCL6 controls Th9 cell development by repressing Il9 transcription. J Immunol. 2014 Jul 01; 193(1):198-207.
BCL6 controls Th9 cell development by repressing Il9 transcription.
Kivisäkk P, Francois K, Mbianda J, Gandhi R, Weiner HL, Khoury SJ
Effect of natalizumab treatment on circulating plasmacytoid dendritic cells: a cross-sectional observational study in patients with multiple sclerosis. PLoS One. 2014; 9(7):e103716.
Effect of natalizumab treatment on circulating plasmacytoid dendritic cells: a cross-sectional observational study in patients with multiple sclerosis.
Tamim H, Irani-Hakime N, Aoun JP, Khoury S, Samaha H, Almawi WY
Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
Seroprevalence of hepatitis C virus (HCV) infection among blood donors: a hospital-based study. Transfus Apher Sci. 2001 Feb; 24(1):29-35.
Seroprevalence of hepatitis C virus (HCV) infection among blood donors: a hospital-based study.
Irani-Hakime N, Aoun J, Khoury S, Samaha HR, Tamim H, Almawi WY
Seroprevalence of hepatitis C infection among health care personnel in Beirut, Lebanon. Am J Infect Control. 2001 Feb; 29(1):20-3.
Seroprevalence of hepatitis C infection among health care personnel in Beirut, Lebanon.
Yamout B, Alroughani R, Al-Jumah M, Khoury S, Abouzeid N, Dahdaleh M, Alsharoqi I, Inshasi J, Hashem S, Zakaria M, ElKallab K, Alsaadi T, Tawfeek T, Bohlega S
Consensus guidelines for the diagnosis and treatment of multiple sclerosis. Curr Med Res Opin. 2013 Jun; 29(6):611-21.
Consensus guidelines for the diagnosis and treatment of multiple sclerosis.
Mouhieddine TH, Darwish H, Fawaz L, Yamout B, Tamim H, Khoury SJ
Risk factors for multiple sclerosis and associations with anti-EBV antibody titers. Clin Immunol. 2015 May; 158(1):59-66.
Risk factors for multiple sclerosis and associations with anti-EBV antibody titers.
Yamout B, Alroughani R, Al-Jumah M, Goueider R, Dahdaleh M, Inshasi J, Hashem S, Alsharoqi I, Sahraian M, Khoury S, Alkawi Z, Koussa S, Zakaria M, Al Khaburi J, Alsaadi T, Bohlega S
Consensus recommendations for the diagnosis and treatment of multiple sclerosis: the Middle East North Africa Committee for Treatment and Research In Multiple Sclerosis (MENACTRIMS). Curr Med Res Opin. 2015; 31(7):1349-61.
Consensus recommendations for the diagnosis and treatment of multiple sclerosis: the Middle East North Africa Committee for Treatment and Research In Multiple Sclerosis (MENACTRIMS).
Yamout BI, Zeineddine MM, Sawaya RA, Khoury SJ
Safety and efficacy of reduced fingolimod dosage treatment. J Neuroimmunol. 2015 Aug 15; 285:13-5.
Safety and efficacy of reduced fingolimod dosage treatment.
Baraka A, Haroun-Bizri S, Khoury S, Chehab IR
Canadian journal of anaesthesia = Journal canadien d'anesthesie
Single vital capacity breath for preoxygenation. Can J Anaesth. 2000 Nov; 47(11):1144-6.
Single vital capacity breath for preoxygenation.
Khalifeh M, Khoury G, Hajj H, Sfeir R, Khoury S, Abi-Saad G
Penetrating missile embolisation. Eur J Vasc Surg. 1993 Jul; 7(4):467-9.
Dabbous A, Khoury SJ, Chehab IR, Bartelmaos T, Khoury G
JSLS : Journal of the Society of Laparoendoscopic Surgeons
Ondansetron versus dehydrobenzoperidol and metoclopramide for management of postoperative nausea in laparoscopic surgery patients. JSLS. 2001 Apr-Jun; 5(2):139-42.
Ondansetron versus dehydrobenzoperidol and metoclopramide for management of postoperative nausea in laparoscopic surgery patients.
Khoury G, Hajj H, Khoury SJ, Basil A, Speir R
Penetrating trauma to the carotid vessels. Eur J Vasc Surg. 1990 Dec; 4(6):607-10.
Penetrating trauma to the carotid vessels.
Carotid endarterectomy. Where do we stand? Middle East J Anaesthesiol. 1988 Jun; 9(5):403-15.
Carotid endarterectomy. Where do we stand?
Multifetal pregnancies. Middle East J Anaesthesiol. 1999 Jun; 15(2):135-52.
Darwish H, Zeinoun P, Ghusn H, Khoury B, Tamim H, Khoury SJ
Serum 25-hydroxyvitamin D predicts cognitive performance in adults. Neuropsychiatr Dis Treat. 2015; 11:2217-23.
Serum 25-hydroxyvitamin D predicts cognitive performance in adults.
Merzaban JS, Imitola J, Starossom SC, Zhu B, Wang Y, Lee J, Ali AJ, Olah M, Abuelela AF, Khoury SJ, Sackstein R
Cell surface glycan engineering of neural stem cells augments neurotropism and improves recovery in a murine model of multiple sclerosis. Glycobiology. 2015 Dec; 25(12):1392-409.
Cell surface glycan engineering of neural stem cells augments neurotropism and improves recovery in a murine model of multiple sclerosis.
Yamout BI, Zeineddine MM, Tamim H, Khoury SJ
Safety and efficacy of fingolimod in clinical practice: The experience of an academic center in the Middle East. J Neuroimmunol. 2015 Dec 15; 289:93-7.
Safety and efficacy of fingolimod in clinical practice: The experience of an academic center in the Middle East.
Kuss R, Khoury S, Richard F, Fourcade R, Frantz P, Capelle JP
[Palliative chemotherapy with 5 FU and CPM in cancer of the prostate with bone metastases resistant to oestrogens. A clinical trial (author's transl)]. J Urol Nephrol (Paris). 1979 Oct-Nov; 85(10-11):649-55.
[Palliative chemotherapy with 5 FU and CPM in cancer of the prostate with bone metastases resistant to oestrogens. A clinical trial (author's transl)].
Alroughani R, Akhtar S, Ahmed SF, Khoury SJ, Al-Hashel JY, Sahraian MA, Al Jumah M, Zeineddine M, Farhat S, Doumiati H, Yamout BI
JC virus seroprevalence and seroconversion in multiple sclerosis cohort: A Middle-Eastern study. J Neurol Sci. 2016 Jan 15; 360:61-5.
JC virus seroprevalence and seroconversion in multiple sclerosis cohort: A Middle-Eastern study.
Küss R, Khoury S, Richard F, Fourcade R, Frantz P, Capelle JP
[Estrogen-resistant prostatic cancer with bone metastases: palliative chemotherapy with 5-fluorouracil and cyclophosphamide]. Nouv Presse Med. 1978 Aug 26-Sep 2; 7(28):2478-9.
[Estrogen-resistant prostatic cancer with bone metastases: palliative chemotherapy with 5-fluorouracil and cyclophosphamide].
Orent W, Mchenry AR, Rao DA, White C, Klein HU, Bassil R, Srivastava G, Replogle JM, Raj T, Frangieh M, Cimpean M, Cuerdon N, Chibnik L, Khoury SJ, Karlson EW, Brenner MB, De Jager P, Bradshaw EM, Elyaman W
Rheumatoid arthritis-associated RBPJ polymorphism alters memory CD4+ T cells. Hum Mol Genet. 2016 Jan 15; 25(2):404-17.
Rheumatoid arthritis-associated RBPJ polymorphism alters memory CD4+ T cells.
Khoury S, Yarows SA, O'Brien TK, Sowers JR
Ambulatory blood pressure monitoring in a nonacademic setting. Effects of age and sex. Am J Hypertens. 1992 Sep; 5(9):616-23.
Ambulatory blood pressure monitoring in a nonacademic setting. Effects of age and sex.
Fawaz L, Mrad MF, Kazan JM, Sayegh S, Akika R, Khoury SJ
Comparative effect of 25(OH)D3 and 1,25(OH)2D3 on Th17 cell differentiation. Clin Immunol. 2016 May; 166-167:59-71.
Comparative effect of 25(OH)D3 and 1,25(OH)2D3 on Th17 cell differentiation.
Dagher MM, Atieh JA, Soubra MK, Khoury SJ, Tamim H, Kaafarani BR
Medical Research Volunteer Program (MRVP): innovative program promoting undergraduate research in the medical field. BMC Med Educ. 2016 Jun 06; 16:160.
Medical Research Volunteer Program (MRVP): innovative program promoting undergraduate research in the medical field.
Impact of IFN-gamma on Neural Stem Cell Repair Potential in EAE
IMMUNOREGULATION IN EAE--ROLE OF T CELL COSTIMULATION
Neural Stem Cells and Regulatory T Cells
Role and Mechanism of PDI-PDL Pathway in EAE
Role and mechanism of negative costimulatory pathways in EAE
11th International Congress of Neuroimmunology
Treatment of Autoimmune Disease by Costimulatory Signal*
Immunoregulation in EAE and novel costimulatory pathways
Immune Regulation of Neural Stem Cell Program in EAE
Yamout BI, Abou Zeid N, Taha AJ, Zeineddine MM, Khoury SJ
Three cases of herpes zoster radiculitis in MS patients treated with natalizumab. Mult Scler Relat Disord. 2016 Sep; 9:122-4.
Three cases of herpes zoster radiculitis in MS patients treated with natalizumab.
Kurdi AT, Bassil R, Olah M, Wu C, Xiao S, Taga M, Frangieh M, Buttrick T, Orent W, Bradshaw EM, Khoury SJ, Elyaman W
Tiam1/Rac1 complex controls Il17a transcription and autoimmunity. Nat Commun. 2016 10 11; 7:13048.
Tiam1/Rac1 complex controls Il17a transcription and autoimmunity.
Bou Fakhredin R, Saade C, Kerek R, El-Jamal L, Khoury SJ, El-Merhi F
Journal of medical imaging and radiation oncology
Imaging in multiple sclerosis: A new spin on lesions. J Med Imaging Radiat Oncol. 2016 Oct; 60(5):577-586.
Imaging in multiple sclerosis: A new spin on lesions.
Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases. Neurotherapeutics. 2017 01; 14(1):135-147.
Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases.
Th9 cells in the pathogenesis of EAE and multiple sclerosis. Semin Immunopathol. 2017 01; 39(1):79-87.
Th9 cells in the pathogenesis of EAE and multiple sclerosis.
Khoury S, Graczyk T, Burnham G, Jurdi M, Goldman L
Eastern Mediterranean health journal = La revue de sante de la Mediterranee orientale = al-Majallah al-sihhiyah li-sharq al-mutawassit
Drinking water system treatment and contamination in Shatila Refugee Camp in Beirut, Lebanon. East Mediterr Health J. 2016 Nov 02; 22(8):568-578.
Drinking water system treatment and contamination in Shatila Refugee Camp in Beirut, Lebanon.
El Ayoubi NK, Ghassan S, Said M, Allam J, Darwish H, Khoury SJ
Retinal measures correlate with cognitive and physical disability in early multiple sclerosis. J Neurol. 2016 Nov; 263(11):2287-2295.
Retinal measures correlate with cognitive and physical disability in early multiple sclerosis.
Azcutia V, Bassil R, Herter JM, Engelbertsen D, Newton G, Autio A, Mayadas T, Lichtman AH, Khoury SJ, Parkos CA, Elyaman W, Luscinskas FW
Defects in CD4+ T cell LFA-1 integrin-dependent adhesion and proliferation protect Cd47-/- mice from EAE. J Leukoc Biol. 2017 02; 101(2):493-505.
Defects in CD4+ T cell LFA-1 integrin-dependent adhesion and proliferation protect Cd47-/- mice from EAE.
Le Journal medical libanais. The Lebanese medical journal
Endoscopic patterns of primary gastric MALT lymphoma. J Med Liban. 1998 May-Jun; 46(3):131-5.
Endoscopic patterns of primary gastric MALT lymphoma.
Abrams P, Andersson KE, Birder L, Brubaker L, Cardozo L, Chapple C, Cottenden A, Davila W, de Ridder D, Dmochowski R, Drake M, Dubeau C, Fry C, Hanno P, Smith JH, Herschorn S, Hosker G, Kelleher C, Koelbl H, Khoury S, Madoff R, Milsom I, Moore K, Newman D, Nitti V, Norton C, Nygaard I, Payne C, Smith A, Staskin D, Tekgul S, Thuroff J, Tubaro A, Vodusek D, Wein A, Wyndaele JJ
Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence. Neurourol Urodyn. 2010; 29(1):213-40.
Fourth International Consultation on Incontinence Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse, and fecal incontinence.
Khoury SJ, Rochon J, Ding L, Byron M, Ryker K, Tosta P, Gao W, Freedman MS, Arnold DL, Sayre PH, Smilek DE
ACCLAIM: A randomized trial of abatacept (CTLA4-Ig) for relapsing-remitting multiple sclerosis. Mult Scler. 2017 Apr; 23(5):686-695.
ACCLAIM: A randomized trial of abatacept (CTLA4-Ig) for relapsing-remitting multiple sclerosis.
Khoury G, Sfeir R, Khalifeh M, Khoury SJ, Nabbout G
Cardiovascular surgery (London, England)
Penetrating trauma to the abdominal vessels. Cardiovasc Surg. 1996 Jun; 4(3):405-7.
Penetrating trauma to the abdominal vessels.
Khoury S, Saliba EK, Oumeish OY, Tawfig MR
Epidemiology of cutaneous leishmaniasis in Jordan: 1983-1992. Int J Dermatol. 1996 Aug; 35(8):566-9.
Epidemiology of cutaneous leishmaniasis in Jordan: 1983-1992.
Chen W, Murphy B, Waaga AM, Willett TA, Russell ME, Khoury SJ, Sayegh MH
Mechanisms of indirect allorecognition in graft rejection: class II MHC allopeptide-specific T cell clones transfer delayed-type hypersensitivity responses in vivo. Transplantation. 1996 Sep 27; 62(6):705-10.
Mechanisms of indirect allorecognition in graft rejection: class II MHC allopeptide-specific T cell clones transfer delayed-type hypersensitivity responses in vivo.
Khoury SJ, Gallon L, Verburg RR, Chandraker A, Peach R, Linsley PS, Turka LA, Hancock WW, Sayegh MH
Ex vivo treatment of antigen-presenting cells with CTLA4Ig and encephalitogenic peptide prevents experimental autoimmune encephalomyelitis in the Lewis rat. J Immunol. 1996 Oct 15; 157(8):3700-5.
Ex vivo treatment of antigen-presenting cells with CTLA4Ig and encephalitogenic peptide prevents experimental autoimmune encephalomyelitis in the Lewis rat.
Santos LM, Lider O, Audette J, Khoury SJ, Weiner HL
Characterization of immunomodulatory properties and accessory cell function of small intestinal epithelial cells. Cell Immunol. 1990 Apr 15; 127(1):26-34.
Characterization of immunomodulatory properties and accessory cell function of small intestinal epithelial cells.
Guleria I, Khosroshahi A, Ansari MJ, Habicht A, Azuma M, Yagita H, Noelle RJ, Coyle A, Mellor AL, Khoury SJ, Sayegh MH
A critical role for the programmed death ligand 1 in fetomaternal tolerance. J Exp Med. 2005 Jul 18; 202(2):231-7.
A critical role for the programmed death ligand 1 in fetomaternal tolerance.
Gallon L, Chandraker A, Issazadeh S, Peach R, Linsley PS, Turka LA, Sayegh MH, Khoury SJ
Differential effects of B7-1 blockade in the rat experimental autoimmune encephalomyelitis model. J Immunol. 1997 Nov 01; 159(9):4212-6.
Differential effects of B7-1 blockade in the rat experimental autoimmune encephalomyelitis model.
Hohol MJ, Olek MJ, Orav EJ, Stazzone L, Hafler DA, Khoury SJ, Dawson DM, Weiner HL
Treatment of progressive multiple sclerosis with pulse cyclophosphamide/methylprednisolone: response to therapy is linked to the duration of progressive disease. Mult Scler. 1999 Dec; 5(6):403-9.
Treatment of progressive multiple sclerosis with pulse cyclophosphamide/methylprednisolone: response to therapy is linked to the duration of progressive disease.
Balashov KE, Comabella M, Ohashi T, Khoury SJ, Weiner HL
Defective regulation of IFNgamma and IL-12 by endogenous IL-10 in progressive MS. Neurology. 2000 Jul 25; 55(2):192-8.
Defective regulation of IFNgamma and IL-12 by endogenous IL-10 in progressive MS.
Frank MH, Denton MD, Alexander SI, Khoury SJ, Sayegh MH, Briscoe DM
Specific MDR1 P-glycoprotein blockade inhibits human alloimmune T cell activation in vitro. J Immunol. 2001 Feb 15; 166(4):2451-9.
Specific MDR1 P-glycoprotein blockade inhibits human alloimmune T cell activation in vitro.
Chitnis T, Salama AD, Grusby MJ, Sayegh MH, Khoury SJ
Defining Th1 and Th2 immune responses in a reciprocal cytokine environment in vivo. J Immunol. 2004 Apr 01; 172(7):4260-5.
Defining Th1 and Th2 immune responses in a reciprocal cytokine environment in vivo.
Hafler DA, Kent SC, Pietrusewicz MJ, Khoury SJ, Weiner HL, Fukaura H
Oral administration of myelin induces antigen-specific TGF-beta 1 secreting T cells in patients with multiple sclerosis. Ann N Y Acad Sci. 1997 Dec 19; 835:120-31.
Oral administration of myelin induces antigen-specific TGF-beta 1 secreting T cells in patients with multiple sclerosis.
Samoilova EB, Horton JL, Zhang H, Khoury SJ, Weiner HL, Chen Y
CTLA-4 is required for the induction of high dose oral tolerance. Int Immunol. 1998 Apr; 10(4):491-8.
CTLA-4 is required for the induction of high dose oral tolerance.
Balashov KE, Olek MJ, Smith DR, Khoury SJ, Weiner HL
Seasonal variation of interferon-gamma production in progressive multiple sclerosis. Ann Neurol. 1998 Nov; 44(5):824-8.
Seasonal variation of interferon-gamma production in progressive multiple sclerosis.
Smith DR, Balashov KE, Hafler DA, Khoury SJ, Weiner HL
Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: increased interleukin-4 production and associated eosinophilia. Ann Neurol. 1997 Sep; 42(3):313-8.
Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: increased interleukin-4 production and associated eosinophilia.
Issazadeh S, Zhang M, Sayegh MH, Khoury SJ
Acquired thymic tolerance: role of CTLA4 in the initiation and maintenance of tolerance in a clinically relevant autoimmune disease model. J Immunol. 1999 Jan 15; 162(2):761-5.
Acquired thymic tolerance: role of CTLA4 in the initiation and maintenance of tolerance in a clinically relevant autoimmune disease model.
Glanz BI, Holland CM, Gauthier SA, Amunwa EL, Liptak Z, Houtchens MK, Sperling RA, Khoury SJ, Guttmann CR, Weiner HL
Cognitive dysfunction in patients with clinically isolated syndromes or newly diagnosed multiple sclerosis. Mult Scler. 2007 Sep; 13(8):1004-10.
Cognitive dysfunction in patients with clinically isolated syndromes or newly diagnosed multiple sclerosis.
Viglietta V, Bourcier K, Buckle GJ, Healy B, Weiner HL, Hafler DA, Egorova S, Guttmann CR, Rusche JR, Khoury SJ
CTLA4Ig treatment in patients with multiple sclerosis: an open-label, phase 1 clinical trial. Neurology. 2008 Sep 16; 71(12):917-24.
CTLA4Ig treatment in patients with multiple sclerosis: an open-label, phase 1 clinical trial.
Liu Y, Bando Y, Vargas-Lowy D, Elyaman W, Khoury SJ, Huang T, Reif K, Chitnis T
The Journal of neuroscience : the official journal of the Society for Neuroscience
CD200R1 agonist attenuates mechanisms of chronic disease in a murine model of multiple sclerosis. J Neurosci. 2010 Feb 10; 30(6):2025-38.
CD200R1 agonist attenuates mechanisms of chronic disease in a murine model of multiple sclerosis.
Waaga AM, Gasser M, Kist-van Holthe JE, Najafian N, Müller A, Vella JP, Womer KL, Chandraker A, Khoury SJ, Sayegh MH
Regulatory functions of self-restricted MHC class II allopeptide-specific Th2 clones in vivo. J Clin Invest. 2001 Apr; 107(7):909-16.
Regulatory functions of self-restricted MHC class II allopeptide-specific Th2 clones in vivo.
Potential of beta2-adrenoceptor agonists as add-on therapy for multiple sclerosis: focus on salbutamol (albuterol). CNS Drugs. 2002; 16(1):1-8.
Potential of beta2-adrenoceptor agonists as add-on therapy for multiple sclerosis: focus on salbutamol (albuterol).
Yip S, Aboody KS, Burns M, Imitola J, Boockvar JA, Allport J, Park KI, Teng YD, Lachyankar M, McIntosh T, O'Rourke DM, Khoury S, Weissleder R, Black PM, Weiss W, Snyder EY
Neural stem cell biology may be well suited for improving brain tumor therapies. Cancer J. 2003 May-Jun; 9(3):189-204.
Neural stem cell biology may be well suited for improving brain tumor therapies.
Khoury SJ, Orav EJ, Guttmann CR, Kikinis R, Jolesz FA, Weiner HL
Changes in serum levels of ICAM and TNF-R correlate with disease activity in multiple sclerosis. Neurology. 1999 Sep 11; 53(4):758-64.
Changes in serum levels of ICAM and TNF-R correlate with disease activity in multiple sclerosis.
O'Connor KC, Chitnis T, Griffin DE, Piyasirisilp S, Bar-Or A, Khoury S, Wucherpfennig KW, Hafler DA
Myelin basic protein-reactive autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients are characterized by low-affinity interactions. J Neuroimmunol. 2003 Mar; 136(1-2):140-8.
Myelin basic protein-reactive autoantibodies in the serum and cerebrospinal fluid of multiple sclerosis patients are characterized by low-affinity interactions.
Ansari MJ, Salama AD, Chitnis T, Smith RN, Yagita H, Akiba H, Yamazaki T, Azuma M, Iwai H, Khoury SJ, Auchincloss H, Sayegh MH
The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice. J Exp Med. 2003 Jul 07; 198(1):63-9.
The programmed death-1 (PD-1) pathway regulates autoimmune diabetes in nonobese diabetic (NOD) mice.
Darwish H, Haddad R, Osman S, Ghassan S, Yamout B, Tamim H, Khoury S
Effect of Vitamin D Replacement on Cognition in Multiple Sclerosis Patients. Sci Rep. 2017 04 04; 7:45926.
Effect of Vitamin D Replacement on Cognition in Multiple Sclerosis Patients.
Imitola J, Comabella M, Chandraker AK, Dangond F, Sayegh MH, Snyder EY, Khoury SJ
Neural stem/progenitor cells express costimulatory molecules that are differentially regulated by inflammatory and apoptotic stimuli. Am J Pathol. 2004 May; 164(5):1615-25.
Neural stem/progenitor cells express costimulatory molecules that are differentially regulated by inflammatory and apoptotic stimuli.
Imitola J, Raddassi K, Park KI, Mueller FJ, Nieto M, Teng YD, Frenkel D, Li J, Sidman RL, Walsh CA, Snyder EY, Khoury SJ
Proceedings of the National Academy of Sciences of the United States of America
Directed migration of neural stem cells to sites of CNS injury by the stromal cell-derived factor 1alpha/CXC chemokine receptor 4 pathway. Proc Natl Acad Sci U S A. 2004 Dec 28; 101(52):18117-22.
Directed migration of neural stem cells to sites of CNS injury by the stromal cell-derived factor 1alpha/CXC chemokine receptor 4 pathway.
Zhu B, Guleria I, Khosroshahi A, Chitnis T, Imitola J, Azuma M, Yagita H, Sayegh MH, Khoury SJ
Differential role of programmed death-ligand 1 [corrected] and programmed death-ligand 2 [corrected] in regulating the susceptibility and chronic progression of experimental autoimmune encephalomyelitis. J Immunol. 2006 Mar 15; 176(6):3480-9.
Differential role of programmed death-ligand 1 [corrected] and programmed death-ligand 2 [corrected] in regulating the susceptibility and chronic progression of experimental autoimmune encephalomyelitis.
The roles of the new negative T cell costimulatory pathways in regulating autoimmunity. Immunity. 2004 May; 20(5):529-38.
The roles of the new negative T cell costimulatory pathways in regulating autoimmunity.
Meier DS, Weiner HL, Khoury SJ, Guttmann CR
Journal of neuroimaging : official journal of the American Society of Neuroimaging
Magnetic resonance imaging surrogates of multiple sclerosis pathology and their relationship to central nervous system atrophy. J Neuroimaging. 2004 Jul; 14(3 Suppl):46S-53S.
Magnetic resonance imaging surrogates of multiple sclerosis pathology and their relationship to central nervous system atrophy.
T cell costimulatory blockade as a novel immune intervention in autoimmune diseases. Clin Dermatol. 2001 Sep-Oct; 19(5):586-91.
T cell costimulatory blockade as a novel immune intervention in autoimmune diseases.
Meisler DM, Tomsak RL, Khoury S, Hanson MR, Schwab IR, Ransohoff RM
Anterior uveitis and multiple sclerosis. Cleve Clin J Med. 1989 Jul-Aug; 56(5):535-8.
Anterior uveitis and multiple sclerosis.
Moodie J, Healy BC, Buckle GJ, Gauthier SA, Glanz BI, Arora A, Ceccarelli A, Tauhid S, Han XM, Venkataraman A, Chitnis T, Khoury SJ, Guttmann CR, Weiner HL, Neema M, Bakshi R
Magnetic resonance disease severity scale (MRDSS) for patients with multiple sclerosis: a longitudinal study. J Neurol Sci. 2012 Apr 15; 315(1-2):49-54.
Magnetic resonance disease severity scale (MRDSS) for patients with multiple sclerosis: a longitudinal study.
Type17 T-cells in central nervous system autoimmunity and tumors. J Clin Immunol. 2012 Aug; 32(4):802-8.
Type17 T-cells in central nervous system autoimmunity and tumors.
Vargas-Lowy D, Kivisäkk P, Gandhi R, Raddassi K, Soltany P, Gorman MP, Khoury SJ, Chitnis T
Increased Th17 response to myelin peptides in pediatric MS. Clin Immunol. 2013 Mar; 146(3):176-84.
Increased Th17 response to myelin peptides in pediatric MS.
Lu, L., S.J. Khoury, M.H. Sayegh, A.W. Thompson.
Dendritic cell tolerogenicity and prospects for dendritic cell-based therapy of allograft rejection and autoimmunity. Dendritic Cells. 1998; 487-511.
Dendritic cell tolerogenicity and prospects for dendritic cell-based therapy of allograft rejection and autoimmunity
Immunological mechanisms in multiple sclerosis. Handbook of Multiple Sclerosis. 1996; 145-155.
Immunological mechanisms in multiple sclerosis
Khoury SJ, Lider O, al-Sabbagh A, Weiner HL
Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein. III. Synergistic effect of lipopolysaccharide. Cell Immunol. 1990 Dec; 131(2):302-10.
Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein. III. Synergistic effect of lipopolysaccharide.
Waaga AM, Murphy B, Chen W, Khoury SJ, Sayegh MH
Class II MHC allopeptide-specific T-cell clones transfer delayed type hypersensitivity responses in vivo. Transplant Proc. 1997 Feb-Mar; 29(1-2):1008-9.
Class II MHC allopeptide-specific T-cell clones transfer delayed type hypersensitivity responses in vivo.
Monsonego A, Imitola J, Zota V, Oida T, Weiner HL
Microglia-mediated nitric oxide cytotoxicity of T cells following amyloid beta-peptide presentation to Th1 cells. J Immunol. 2003 Sep 01; 171(5):2216-24.
Microglia-mediated nitric oxide cytotoxicity of T cells following amyloid beta-peptide presentation to Th1 cells.
Mueller FJ, McKercher SR, Imitola J, Loring JF, Yip S, Khoury SJ, Snyder EY
Ernst Schering Research Foundation workshop
At the interface of the immune system and the nervous system: how neuroinflammation modulates the fate of neural progenitors in vivo. Ernst Schering Res Found Workshop. 2005; (53):83-114.
At the interface of the immune system and the nervous system: how neuroinflammation modulates the fate of neural progenitors in vivo.
Genetic programs and responses of neural stem/progenitor cells during demyelination: potential insights into repair mechanisms in multiple sclerosis. Physiol Genomics. 2003 Aug 15; 14(3):171-97.
Genetic programs and responses of neural stem/progenitor cells during demyelination: potential insights into repair mechanisms in multiple sclerosis.
Krishnamoorthy M, Roy-Chaudhury P, Wang Y, Sinha Roy A, Zhang J, Khoury S, Munda R, Banerjee R
Measurement of hemodynamic and anatomic parameters in a swine arteriovenous fistula model. J Vasc Access. 2008 Jan-Mar; 9(1):28-34.
Measurement of hemodynamic and anatomic parameters in a swine arteriovenous fistula model.
Issazadeh S, Navikas V, Schaub M, Sayegh M, Khoury S
Kinetics of expression of costimulatory molecules and their ligands in murine relapsing experimental autoimmune encephalomyelitis in vivo. J Immunol. 1998 Aug 01; 161(3):1104-12.
Kinetics of expression of costimulatory molecules and their ligands in murine relapsing experimental autoimmune encephalomyelitis in vivo.
Weiner HL, Guttmann CR, Khoury SJ, Orav EJ, Hohol MJ, Kikinis R, Jolesz FA
Serial magnetic resonance imaging in multiple sclerosis: correlation with attacks, disability, and disease stage. J Neuroimmunol. 2000 May 01; 104(2):164-73.
Serial magnetic resonance imaging in multiple sclerosis: correlation with attacks, disability, and disease stage.
Khoury SJ, Guttmann CR, Orav EJ, Kikinis R, Jolesz FA, Weiner HL
Changes in activated T cells in the blood correlate with disease activity in multiple sclerosis. Arch Neurol. 2000 Aug; 57(8):1183-9.
Changes in activated T cells in the blood correlate with disease activity in multiple sclerosis.
Zhu B, Kennedy JK, Wang Y, Sandoval-Garcia C, Cao L, Xiao S, Wu C, Elyaman W, Khoury SJ
Plasticity of Ly-6C(hi) myeloid cells in T cell regulation. J Immunol. 2011 Sep 01; 187(5):2418-32.
Plasticity of Ly-6C(hi) myeloid cells in T cell regulation.
Magee CC, Denton MD, Womer KL, Khoury SJ, Sayegh MH
Assessment by flow cytometry of intracellular cytokine production in the peripheral blood cells of renal transplant recipients. Clin Transplant. 2004 Aug; 18(4):395-401.
Assessment by flow cytometry of intracellular cytokine production in the peripheral blood cells of renal transplant recipients.
Nieto M, Monuki ES, Tang H, Imitola J, Haubst N, Khoury SJ, Cunningham J, Gotz M, Walsh CA
Expression of Cux-1 and Cux-2 in the subventricular zone and upper layers II-IV of the cerebral cortex. J Comp Neurol. 2004 Nov 08; 479(2):168-80.
Expression of Cux-1 and Cux-2 in the subventricular zone and upper layers II-IV of the cerebral cortex.
Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, Zheng XX, Strom TB, Kuchroo VK
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 2005 Dec; 6(12):1245-52.
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity.
Mrad MF, El Ayoubi NK, Esmerian MO, Kazan JM, Khoury SJ
Effect of vitamin D replacement on immunological biomarkers in patients with multiple sclerosis. Clin Immunol. 2017 08; 181:9-15.
Effect of vitamin D replacement on immunological biomarkers in patients with multiple sclerosis.
Waaga AM, Chandraker A, Spadafora-Ferreira M, Iyengar AR, Khoury SJ, Carpenter CB, Sayegh MH
Mechanisms of indirect allorecognition: characterization of MHC class II allopeptide-specific T helper cell clones from animals undergoing acute allograft rejection. Transplantation. 1998 Apr 15; 65(7):876-83.
Mechanisms of indirect allorecognition: characterization of MHC class II allopeptide-specific T helper cell clones from animals undergoing acute allograft rejection.
Kaneko S, Wang J, Kaneko M, Yiu G, Hurrell JM, Chitnis T, Khoury SJ, He Z
Protecting axonal degeneration by increasing nicotinamide adenine dinucleotide levels in experimental autoimmune encephalomyelitis models. J Neurosci. 2006 Sep 20; 26(38):9794-804.
Protecting axonal degeneration by increasing nicotinamide adenine dinucleotide levels in experimental autoimmune encephalomyelitis models.
Opposite functions of STAT3 and Smad3 in regulating Tiam1 expression in Th17 cells. Small GTPases. 2020 01; 11(1):62-68.
Opposite functions of STAT3 and Smad3 in regulating Tiam1 expression in Th17 cells.
Rasmussen S, Wang Y, Kivisäkk P, Bronson RT, Meyer M, Imitola J, Khoury SJ
Persistent activation of microglia is associated with neuronal dysfunction of callosal projecting pathways and multiple sclerosis-like lesions in relapsing--remitting experimental autoimmune encephalomyelitis. Brain. 2007 Nov; 130(Pt 11):2816-29.
Persistent activation of microglia is associated with neuronal dysfunction of callosal projecting pathways and multiple sclerosis-like lesions in relapsing--remitting experimental autoimmune encephalomyelitis.
Increased percentage of IL-12+ monocytes in the blood correlates with the presence of active MRI lesions in MS. J Neuroimmunol. 2001 Sep 03; 119(1):145-9.
Increased percentage of IL-12+ monocytes in the blood correlates with the presence of active MRI lesions in MS.
Neema M, Arora A, Healy BC, Guss ZD, Brass SD, Duan Y, Buckle GJ, Glanz BI, Stazzone L, Khoury SJ, Weiner HL, Guttmann CR, Bakshi R
Deep gray matter involvement on brain MRI scans is associated with clinical progression in multiple sclerosis. J Neuroimaging. 2009 Jan; 19(1):3-8.
Deep gray matter involvement on brain MRI scans is associated with clinical progression in multiple sclerosis.
Kivisäkk P, Healy BC, Viglietta V, Quintana FJ, Hootstein MA, Weiner HL, Khoury SJ
Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells. Neurology. 2009 Jun 02; 72(22):1922-30.
Natalizumab treatment is associated with peripheral sequestration of proinflammatory T cells.
Gross R, Healy BC, Cepok S, Chitnis T, Khoury SJ, Hemmer B, Weiner HL, Hafler DA, De Jager PL
Population structure and HLA DRB1 1501 in the response of subjects with multiple sclerosis to first-line treatments. J Neuroimmunol. 2011 Apr; 233(1-2):168-74.
Population structure and HLA DRB1 1501 in the response of subjects with multiple sclerosis to first-line treatments.
Benou C, Wang Y, Imitola J, VanVlerken L, Chandras C, Karalis KP, Khoury SJ
Corticotropin-releasing hormone contributes to the peripheral inflammatory response in experimental autoimmune encephalomyelitis. J Immunol. 2005 May 01; 174(9):5407-13.
Corticotropin-releasing hormone contributes to the peripheral inflammatory response in experimental autoimmune encephalomyelitis.
Hohol MJ, Khoury SJ, Cook SL, Orav EJ, Hafler DA, Weiner HL
Three-year open protocol continuation study of oral tolerization with myelin antigens in multiple sclerosis and design of a phase III pivotal trial. Ann N Y Acad Sci. 1996 Feb 13; 778:243-50.
Three-year open protocol continuation study of oral tolerization with myelin antigens in multiple sclerosis and design of a phase III pivotal trial.
Insights into the molecular pathogenesis of progression in multiple sclerosis: potential implications for future therapies. Arch Neurol. 2006 Jan; 63(1):25-33.
Insights into the molecular pathogenesis of progression in multiple sclerosis: potential implications for future therapies.
Gauthier SA, Berger AM, Liptak Z, Duan Y, Egorova S, Buckle GJ, Glanz BI, Khoury SJ, Bakshi R, Weiner HL, Guttmann CR
Rate of brain atrophy in benign vs early multiple sclerosis. Arch Neurol. 2009 Feb; 66(2):234-7.
Rate of brain atrophy in benign vs early multiple sclerosis.
McLaughlin KA, Chitnis T, Newcombe J, Franz B, Kennedy J, McArdel S, Kuhle J, Kappos L, Rostasy K, Pohl D, Gagne D, Ness JM, Tenembaum S, O'Connor KC, Viglietta V, Wong SJ, Tavakoli NP, de Seze J, Idrissova Z, Khoury SJ, Bar-Or A, Hafler DA, Banwell B, Wucherpfennig KW
Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. J Immunol. 2009 Sep 15; 183(6):4067-76.
Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis.
Kent SC, Fukaura H, Pietrusewicz MJ, Khoury SJ, Weiner HL, Hafler DA
Oral administration of myelin induces antigen-specific TGF-beta 1-secreting T cells in multiple sclerosis patients. Ann N Y Acad Sci. 1997 Apr 05; 815:412-22.
Oral administration of myelin induces antigen-specific TGF-beta 1-secreting T cells in multiple sclerosis patients.
Ali EN, Healy BC, Stazzone LA, Brown BA, Weiner HL, Khoury SJ
Daclizumab in treatment of multiple sclerosis patients. Mult Scler. 2009 Feb; 15(2):272-4.
Daclizumab in treatment of multiple sclerosis patients.
Liguori M, Meier DS, Hildenbrand P, Healy BC, Chitnis T, Baruch NF, Khoury SJ, Weiner HL, Bakshi R, Barkhof F, Guttmann CR
One year activity on subtraction MRI predicts subsequent 4 year activity and progression in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2011 Oct; 82(10):1125-31.
One year activity on subtraction MRI predicts subsequent 4 year activity and progression in multiple sclerosis.
Starossom SC, Imitola J, Wang Y, Cao L, Khoury SJ
Subventricular zone microglia transcriptional networks. Brain Behav Immun. 2011 Jul; 25(5):991-9.
Subventricular zone microglia transcriptional networks.
Purwar R, Schlapbach C, Xiao S, Kang HS, Elyaman W, Jiang X, Jetten AM, Khoury SJ, Fuhlbrigge RC, Kuchroo VK, Clark RA, Kupper TS
Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells. Nat Med. 2012 Aug; 18(8):1248-53.
Robust tumor immunity to melanoma mediated by interleukin-9-producing T cells.
Role of Neural Stem and Oligodendrocyte Progenitor Cells in Demyelinating Diseases: Insights into Disease Mechanisms and Therapeutic Potential. Disorders of myelin in the central and peripheral nervous system. 2002; 57-81.
Role of Neural Stem and Oligodendrocyte Progenitor Cells in Demyelinating Diseases: Insights into Disease Mechanisms and Therapeutic Potential
Elyaman W, Bradshaw EM, Uyttenhove C, Dardalhon V, Awasthi A, Imitola J, Bettelli E, Oukka M, van Snick J, Renauld JC, Kuchroo VK, Khoury SJ
IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells. Proc Natl Acad Sci U S A. 2009 Aug 04; 106(31):12885-90.
IL-9 induces differentiation of TH17 cells and enhances function of FoxP3+ natural regulatory T cells.
Ilan Y, Zigmond E, Lalazar G, Dembinsky A, Ben Ya'acov A, Hemed N, Kasis I, Axelrod E, Zolotarov L, Klein A, El Haj M, Gandhi R, Baecher-Allan C, Wu H, Murugaiyan G, Kivisakk P, Farez MF, Quintana FJ, Khoury SJ, Weiner HL
Oral administration of OKT3 monoclonal antibody to human subjects induces a dose-dependent immunologic effect in T cells and dendritic cells. J Clin Immunol. 2010 Jan; 30(1):167-77.
Oral administration of OKT3 monoclonal antibody to human subjects induces a dose-dependent immunologic effect in T cells and dendritic cells.
Yamout BI, Said M, Hannoun S, Zeineddine M, Massouh J, Khoury SJ
Rebound syndrome after teriflunomide cessation in a patient with multiple sclerosis. J Neurol Sci. 2017 Sep 15; 380:79-81.
Rebound syndrome after teriflunomide cessation in a patient with multiple sclerosis.
Balashov KE, Khoury SJ, Hafler DA, Weiner HL
Inhibition of T cell responses by activated human CD8+ T cells is mediated by interferon-gamma and is defective in chronic progressive multiple sclerosis. J Clin Invest. 1995 Jun; 95(6):2711-9.
Inhibition of T cell responses by activated human CD8+ T cells is mediated by interferon-gamma and is defective in chronic progressive multiple sclerosis.
Weiner HL, Friedman A, Miller A, Khoury SJ, al-Sabbagh A, Santos L, Sayegh M, Nussenblatt RB, Trentham DE, Hafler DA
Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu Rev Immunol. 1994; 12:809-37.
Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens.
Hancock WW, Khoury SJ, Carpenter CB, Sayegh MH
Differential effects of oral versus intrathymic administration of polymorphic major histocompatibility complex class II peptides on mononuclear and endothelial cell activation and cytokine expression during a delayed-type hypersensitivity response. Am J Pathol. 1994 Jun; 144(6):1149-58.
Differential effects of oral versus intrathymic administration of polymorphic major histocompatibility complex class II peptides on mononuclear and endothelial cell activation and cytokine expression during a delayed-type hypersensitivity response.
Takashima H, Smith DR, Fukaura H, Khoury SJ, Hafler DA, Weiner HL
Pulse cyclophosphamide plus methylprednisolone induces myelin-antigen-specific IL-4-secreting T cells in multiple sclerosis patients. Clin Immunol Immunopathol. 1998 Jul; 88(1):28-34.
Pulse cyclophosphamide plus methylprednisolone induces myelin-antigen-specific IL-4-secreting T cells in multiple sclerosis patients.
Comabella M, Balashov K, Issazadeh S, Smith D, Weiner HL, Khoury SJ
Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy. J Clin Invest. 1998 Aug 15; 102(4):671-8.
Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy.
Sayegh MH, Khoury SJ, Hancock WW, Weiner HL, Carpenter CB
Induction of immunity and oral tolerance with polymorphic class II major histocompatibility complex allopeptides in the rat. Proc Natl Acad Sci U S A. 1992 Aug 15; 89(16):7762-6.
Induction of immunity and oral tolerance with polymorphic class II major histocompatibility complex allopeptides in the rat.
Najafian N, Chitnis T, Salama AD, Zhu B, Benou C, Yuan X, Clarkson MR, Sayegh MH, Khoury SJ
Regulatory functions of CD8+CD28- T cells in an autoimmune disease model. J Clin Invest. 2003 Oct; 112(7):1037-48.
Regulatory functions of CD8+CD28- T cells in an autoimmune disease model.
Sheen VL, Ganesh VS, Topcu M, Sebire G, Bodell A, Hill RS, Grant PE, Shugart YY, Imitola J, Khoury SJ, Guerrini R, Walsh CA
Mutations in ARFGEF2 implicate vesicle trafficking in neural progenitor proliferation and migration in the human cerebral cortex. Nat Genet. 2004 Jan; 36(1):69-76.
Mutations in ARFGEF2 implicate vesicle trafficking in neural progenitor proliferation and migration in the human cerebral cortex.
Elyaman W, Kivisäkk P, Reddy J, Chitnis T, Raddassi K, Imitola J, Bradshaw E, Kuchroo VK, Yagita H, Sayegh MH, Khoury SJ
Distinct functions of autoreactive memory and effector CD4+ T cells in experimental autoimmune encephalomyelitis. Am J Pathol. 2008 Aug; 173(2):411-22.
Distinct functions of autoreactive memory and effector CD4+ T cells in experimental autoimmune encephalomyelitis.
Imitola J, Côté D, Rasmussen S, Xie XS, Liu Y, Chitnis T, Sidman RL, Lin CP, Khoury SJ
Multimodal coherent anti-Stokes Raman scattering microscopy reveals microglia-associated myelin and axonal dysfunction in multiple sclerosis-like lesions in mice. J Biomed Opt. 2011 Feb; 16(2):021109.
Multimodal coherent anti-Stokes Raman scattering microscopy reveals microglia-associated myelin and axonal dysfunction in multiple sclerosis-like lesions in mice.
Holland CM, Charil A, Csapo I, Liptak Z, Ichise M, Khoury SJ, Bakshi R, Weiner HL, Guttmann CR
The relationship between normal cerebral perfusion patterns and white matter lesion distribution in 1,249 patients with multiple sclerosis. J Neuroimaging. 2012 Apr; 22(2):129-36.
The relationship between normal cerebral perfusion patterns and white matter lesion distribution in 1,249 patients with multiple sclerosis.
Balashov KE, Smith DR, Khoury SJ, Hafler DA, Weiner HL
Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand. Proc Natl Acad Sci U S A. 1997 Jan 21; 94(2):599-603.
Increased interleukin 12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand.
Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and prostaglandin E expression in the brain. J Exp Med. 1992 Nov 01; 176(5):1355-64.
Oral tolerance to myelin basic protein and natural recovery from experimental autoimmune encephalomyelitis are associated with downregulation of inflammatory cytokines and differential upregulation of transforming growth factor beta, interleukin 4, and prostaglandin E expression in the brain.
Chitnis T, Najafian N, Abdallah KA, Dong V, Yagita H, Sayegh MH, Khoury SJ
CD28-independent induction of experimental autoimmune encephalomyelitis. J Clin Invest. 2001 Mar; 107(5):575-83.
CD28-independent induction of experimental autoimmune encephalomyelitis.
Karni A, Koldzic DN, Bharanidharan P, Khoury SJ, Weiner HL
IL-18 is linked to raised IFN-gamma in multiple sclerosis and is induced by activated CD4(+) T cells via CD40-CD40 ligand interactions. J Neuroimmunol. 2002 Apr; 125(1-2):134-40.
IL-18 is linked to raised IFN-gamma in multiple sclerosis and is induced by activated CD4(+) T cells via CD40-CD40 ligand interactions.
Salama AD, Chitnis T, Imitola J, Ansari MJ, Akiba H, Tushima F, Azuma M, Yagita H, Sayegh MH, Khoury SJ
Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J Exp Med. 2003 Jul 07; 198(1):71-8.
Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis.
Monsonego A, Imitola J, Petrovic S, Zota V, Nemirovsky A, Baron R, Fisher Y, Owens T, Weiner HL
Abeta-induced meningoencephalitis is IFN-gamma-dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A. 2006 Mar 28; 103(13):5048-53.
Abeta-induced meningoencephalitis is IFN-gamma-dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer's disease.
Prospects for neural stem cell-based therapies for neurological diseases. Neurotherapeutics. 2007 Oct; 4(4):701-14.
Prospects for neural stem cell-based therapies for neurological diseases.
Quintana FJ, Farez MF, Viglietta V, Iglesias AH, Merbl Y, Izquierdo G, Lucas M, Basso AS, Khoury SJ, Lucchinetti CF, Cohen IR, Weiner HL
Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis. Proc Natl Acad Sci U S A. 2008 Dec 02; 105(48):18889-94.
Antigen microarrays identify unique serum autoantibody signatures in clinical and pathologic subtypes of multiple sclerosis.
Neurological Therapeutics: Principles and Practice
Pregnancy and Multiple Sclerosis: Therapeutic Aspects. Neurological Therapeutics: Principles and Practice. 2003; 2(149):1552-1555.
Pregnancy and Multiple Sclerosis: Therapeutic Aspects
Current drug targets. Immune, endocrine and metabolic disorders
Therapeutic strategies to prevent neurodegeneration and promote regeneration in multiple sclerosis. Curr Drug Targets Immune Endocr Metabol Disord. 2005 Mar; 5(1):11-26.
Curr Drug Targets Immune Endocr Metabol Disord
Therapeutic strategies to prevent neurodegeneration and promote regeneration in multiple sclerosis.
Zhu B, Bando Y, Xiao S, Yang K, Anderson AC, Kuchroo VK, Khoury SJ
CD11b+Ly-6C(hi) suppressive monocytes in experimental autoimmune encephalomyelitis. J Immunol. 2007 Oct 15; 179(8):5228-37.
CD11b+Ly-6C(hi) suppressive monocytes in experimental autoimmune encephalomyelitis.
Yamout BI, Khoury SJ, Ayyoubi N, Doumiati H, Fakhreddine M, Ahmed SF, Tamim H, Al-Hashel JY, Behbehani R, Alroughani R
Alternative diagnoses in patients referred to specialized centers for suspected MS. Mult Scler Relat Disord. 2017 Nov; 18:85-89.
Alternative diagnoses in patients referred to specialized centers for suspected MS.
Stankiewicz JM, Glanz BI, Healy BC, Arora A, Neema M, Benedict RH, Guss ZD, Tauhid S, Buckle GJ, Houtchens MK, Khoury SJ, Weiner HL, Guttmann CR, Bakshi R
Brain MRI lesion load at 1.5T and 3T versus clinical status in multiple sclerosis. J Neuroimaging. 2011 Apr; 21(2):e50-6.
Brain MRI lesion load at 1.5T and 3T versus clinical status in multiple sclerosis.
Prat A, Biernacki K, Saroli T, Orav JE, Guttmann CR, Weiner HL, Khoury SJ, Antel JP
Kinin B1 receptor expression on multiple sclerosis mononuclear cells: correlation with magnetic resonance imaging T2-weighted lesion volume and clinical disability. Arch Neurol. 2005 May; 62(5):795-800.
Kinin B1 receptor expression on multiple sclerosis mononuclear cells: correlation with magnetic resonance imaging T2-weighted lesion volume and clinical disability.
Therapeutic strategies in multiple sclerosis. Clin Immunol. 2012 Jan; 142(1):1.
Therapeutic strategies in multiple sclerosis.
Zhu B, Trikudanathan S, Zozulya AL, Sandoval-Garcia C, Kennedy JK, Atochina O, Norberg T, Castagner B, Seeberger P, Fabry Z, Harn D, Khoury SJ, Guleria I
Immune modulation by Lacto-N-fucopentaose III in experimental autoimmune encephalomyelitis. Clin Immunol. 2012 Mar; 142(3):351-61.
Immune modulation by Lacto-N-fucopentaose III in experimental autoimmune encephalomyelitis.
Pluchino S, Muzio L, Imitola J, Deleidi M, Alfaro-Cervello C, Salani G, Porcheri C, Brambilla E, Cavasinni F, Bergamaschi A, Garcia-Verdugo JM, Comi G, Khoury SJ, Martino G
Persistent inflammation alters the function of the endogenous brain stem cell compartment. Brain. 2008 Oct; 131(Pt 10):2564-78.
Persistent inflammation alters the function of the endogenous brain stem cell compartment.
Multiple Sclerosis: tissue destruction and repair,
IL-12: immunological staging of Multiple Sclerosis and measure of response to therapy. Multiple Sclerosis: tissue destruction and repair,. 2001; 219-224.
IL-12: immunological staging of Multiple Sclerosis and measure of response to therapy
Weiner, H.L., M.J. Hohol, S.J. Khoury, D.M. Dawson, D.A. Hafler
Therapy of multiple sclerosis. Neurologic Clinics. 1995; 173-196.
Gauthier SA, Mandel M, Guttmann CR, Glanz BI, Khoury SJ, Betensky RA, Weiner HL
Predicting short-term disability in multiple sclerosis. Neurology. 2007 Jun 12; 68(24):2059-65.
Predicting short-term disability in multiple sclerosis.
Liguori M, Healy BC, Glanz BI, Khoury SJ, Moscufo N, Weiner HL, De Jager PL, Guttmann CR
HLA (A-B-C and -DRB1) alleles and brain MRI changes in multiple sclerosis: a longitudinal study. Genes Immun. 2011 Apr; 12(3):183-90.
HLA (A-B-C and -DRB1) alleles and brain MRI changes in multiple sclerosis: a longitudinal study.
Elyaman W, Khoury SJ, Scott DW, De Groot AS
Potential application of tregitopes as immunomodulating agents in multiple sclerosis. Neurol Res Int. 2011; 2011:256460.
Potential application of tregitopes as immunomodulating agents in multiple sclerosis.
Bakshi R, Neema M, Healy BC, Liptak Z, Betensky RA, Buckle GJ, Gauthier SA, Stankiewicz J, Meier D, Egorova S, Arora A, Guss ZD, Glanz B, Khoury SJ, Guttmann CR, Weiner HL
Predicting clinical progression in multiple sclerosis with the magnetic resonance disease severity scale. Arch Neurol. 2008 Nov; 65(11):1449-53.
Predicting clinical progression in multiple sclerosis with the magnetic resonance disease severity scale.
Immunopathogenesis of multiple sclerosis. Clin Immunol. 2012 Jan; 142(1):2-8.
Immunopathogenesis of multiple sclerosis.
Emerging disease-modifying therapies. Multiple Sclerosis Therapeutics. 2003; 515-522.
Induction of immunity and oral tolerance to alloantigen by polymorphic class II major histocompatibility complex allopeptides in the rat. Transplant Proc. 1993 Feb; 25(1 Pt 1):357-8.
Induction of immunity and oral tolerance to alloantigen by polymorphic class II major histocompatibility complex allopeptides in the rat.
Mechanisms of oral tolerance by MHC peptides. Ann N Y Acad Sci. 1996 Feb 13; 778:338-45.
Mechanisms of oral tolerance by MHC peptides.
Gauthier SA, Glanz BI, Mandel M, Tsagkaropoulos A, Neema M, Stankiewicz J, Arora A, Duan Y, Liptak Z, Egorova S, Buckle GJ, Bakshi R, Guttmann CR, Khoury SJ, Weiner HL
Incidence and factors associated with treatment failure in the CLIMB multiple sclerosis cohort study. J Neurol Sci. 2009 Sep 15; 284(1-2):116-9.
Incidence and factors associated with treatment failure in the CLIMB multiple sclerosis cohort study.
Elyaman W, Bassil R, Bradshaw EM, Orent W, Lahoud Y, Zhu B, Radtke F, Yagita H, Khoury SJ
Notch receptors and Smad3 signaling cooperate in the induction of interleukin-9-producing T cells. Immunity. 2012 Apr 20; 36(4):623-34.
Notch receptors and Smad3 signaling cooperate in the induction of interleukin-9-producing T cells.
Buttrick TS, Wang W, Yung C, Trieu KG, Patel K, Khoury SJ, Ai X, Elyaman W
Foxo1 Promotes Th9 Cell Differentiation and Airway Allergy. Sci Rep. 2018 01 16; 8(1):818.
Foxo1 Promotes Th9 Cell Differentiation and Airway Allergy.
Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients. J Clin Invest. 1996 Jul 01; 98(1):70-7.
Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients.
Bove R, Chitnis T, Cree BA, Tintoré M, Naegelin Y, Uitdehaag BM, Kappos L, Khoury SJ, Montalban X, Hauser SL, Weiner HL
SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts. Mult Scler. 2018 10; 24(11):1485-1498.
SUMMIT (Serially Unified Multicenter Multiple Sclerosis Investigation): creating a repository of deeply phenotyped contemporary multiple sclerosis cohorts.
Bassil R, Zhu B, Lahoud Y, Riella LV, Yagita H, Elyaman W, Khoury SJ
Notch ligand delta-like 4 blockade alleviates experimental autoimmune encephalomyelitis by promoting regulatory T cell development. J Immunol. 2011 Sep 01; 187(5):2322-8.
Notch ligand delta-like 4 blockade alleviates experimental autoimmune encephalomyelitis by promoting regulatory T cell development.
Chen W, Issazadeh S, Sayegh MH, Khoury SJ
In vivo mechanisms of acquired thymic tolerance. Cell Immunol. 1997 Aug 01; 179(2):165-73.
In vivo mechanisms of acquired thymic tolerance.
Multiple sclerosis: what have we learned from magnetic resonance imaging studies? Arch Intern Med. 1998 Mar 23; 158(6):565-73.
Multiple sclerosis: what have we learned from magnetic resonance imaging studies?
Schaub M, Issazadeh S, Stadlbauer TH, Peach R, Sayegh MH, Khoury SJ
Costimulatory signal blockade in murine relapsing experimental autoimmune encephalomyelitis. J Neuroimmunol. 1999 May 03; 96(2):158-66.
Costimulatory signal blockade in murine relapsing experimental autoimmune encephalomyelitis.
Kishimoto K, Sandner S, Imitola J, Sho M, Li Y, Langmuir PB, Rothstein DM, Strom TB, Turka LA, Sayegh MH
Th1 cytokines, programmed cell death, and alloreactive T cell clone size in transplant tolerance. J Clin Invest. 2002 Jun; 109(11):1471-9.
Th1 cytokines, programmed cell death, and alloreactive T cell clone size in transplant tolerance.
Laplaud DA, Berthelot L, Miqueu P, Bourcier K, Moynard J, Oudinet Y, Guillet M, Ruiz C, Oden N, Brouard S, Guttmann CR, Weiner HL, Khoury SJ, Soulillou JP
Serial blood T cell repertoire alterations in multiple sclerosis patients; correlation with clinical and MRI parameters. J Neuroimmunol. 2006 Aug; 177(1-2):151-60.
Serial blood T cell repertoire alterations in multiple sclerosis patients; correlation with clinical and MRI parameters.
Mechanisms of acquired thymic tolerance in vivo: intrathymic injection of antigen induces apoptosis of thymocytes and peripheral T cell anergy. J Immunol. 1998 Feb 01; 160(3):1504-8.
Mechanisms of acquired thymic tolerance in vivo: intrathymic injection of antigen induces apoptosis of thymocytes and peripheral T cell anergy.
Multiple Sclerosis. Women and Health. 1999; 686-703.
Comabella M, Imitola J, Weiner HL, Khoury SJ
Interferon-beta treatment alters peripheral blood monocytes chemokine production in MS patients. J Neuroimmunol. 2002 May; 126(1-2):205-12.
Interferon-beta treatment alters peripheral blood monocytes chemokine production in MS patients.
Hohol MJ, Guttmann CR, Orav J, Mackin GA, Kikinis R, Khoury SJ, Jolesz FA, Weiner HL
Serial neuropsychological assessment and magnetic resonance imaging analysis in multiple sclerosis. Arch Neurol. 1997 Aug; 54(8):1018-25.
Serial neuropsychological assessment and magnetic resonance imaging analysis in multiple sclerosis.